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Monocytes as Gene Therapy Vectors for the Treatment of Alzheimer’s Disease
Lori Ann Lebson
ABSTRACT
The accumulation of amyloid-β protein (Aβ) in Alzheimer’s disease (AD) is
a well known pathological event. Decreasing the production or increasing the
degradation of Aβ is therefore thought to serve as a potential therapeutic
intervention in AD. Recent in vitro and in vivo studies have suggested that certain
proteases may be involved in the catabolism of Aβ and defects in the
degradation of Aβ could contribute to AD disease progression. Studies
implicating the homing of monocytes to regions of CNS damage have led to the
idea that it may be possible to use genetically modified monocytes to carry
exogenous genes of interest into the brain or other organs for the purposes of
gene therapy.
To determine the time course of monocyte recruitment into the brain
during the neurodegenerative damage characteristic of Alzheimer’s disease, we
used transplanted GFP labeled bone marrow monocytes to characterize the
kinetics that peripheral monocytes display once injected into the circulation. We
determined the half life of bone marrow derived monocytes after one injection
into the peripheral circulation, and found this time to be 1.5 hours post injection.
We also examined the effects of the APP+PS1 transgene on the recruitment of
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peripheral monocytes and showed that these cells are actively recruited to the
brains in AD transgenic mouse models compared to non transgenic mice.
As an approach to increase expression of NEP in a transgenic mouse
model of AD, we developed an ex vivo gene therapy method utilizing bone
marrow monocytes from GFP mice. These monocytes were transfected with a
NEP construct designed to express either a secreted form of NEP or a form
which lacks any enzyme activity.

Monocytes were administered through a

microvascular port twice a week for two months and we observed recruitment of
bone marrow-derived monocytes into the CNS. In addition, we found significant
reductions in both Aβ and Congo red staining in the NEP-S injected mice only.
These studies show that putting monocytes together with an amyloid degrading
enzyme such as neprilysin offers a powerful novel therapeutic tool for the
treatment of AD.
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INTRODUCTION
ALZHEIMER’S DISEASE
Alzheimer’s Disease (AD) is an age-related neurodegenerative disorder
and is the most common form of senile dementia among the elderly. Clinically
AD is characterized by a decline in cognitive performance, memory deficits,
confusion and behavioral changes (Selkoe 2001). Currently there is not a direct
objective test for AD, therefore only post mortem assessment of the brain offers
a diagnosis based on the presence of the classic histopathological features of
AD including the presence of amyloid β plaques, neurofibrillary tangles and
neuronal atrophy (Hardy and Selkoe 2002). Although the cause of the disease
remains unknown and most of the reported cases are sporadic, a small fraction
of AD patients genetically inherit the disease through autosomal dominant
inheritance which results in disease onset before the age of 65. Mutations that
increase the Aβ deposition are associated with the familial form of AD termed
familial AD (FAD). Currently, mutations in amyloid precursor protein (APP),
presenilin 1 (PS1), and presenilin 2 (PS2) are thought to have a part in the
development of the disease and are implicated in the transport and processing
of APP (Nunan and Small 2002). These mutations all result in an increased
production of Aβ42 which is more prone to fibrillogenesis. The ability of the APP
gene mutation to give rise to AD neuropathology suggests that amyloid

deposition is one of the pivotal events in the pathogenesis of AD. This supports
the amyloid cascade hypothesis which proposes that the accumulation of Aβ
results in AD pathogenesis.

APP STRUCTURE, FUNCTION, AND METABOLISM
The proteolytic processing of the amyloid precursor protein plays a key
role in the development of AD. APP is located on chromosome 21 and is a
single transmembrane glycoprotein that is translocated into the ER via its signal
peptide, then postranslationally modified through the secretory pathway (Nunan
and Small 2002). APP is expressed in the heart, kidneys, lungs, spleen and
intestines as well as in the brain. The cleavage of the APP can occur through
two different pathways, both of which involve the action of proteases known as
secretases. Cleavage of APP by β-secretase at the N-terminus results in βAPPs and a membrane bound C-terminal fragment (CTF) C99 (Selkoe 2001).
Further cleavage of the CTF C99 by γ secretases releases Aβ1-40 and Aβ1-42.
An alternative pathway that involves the cleavage of APP is through α–
secretase which releases a large α-APPs fragment into the extracellular space
and also generates another CTF, namely C83. C83 is further processed by γ
secretase, releasing a fragment known as p3 (Selkoe 2001).
Amyloid β (Aβ) is a 4 kDa peptide derived from the proteolytic cleavage
of APP (Morishima-Kawashima and Ihara 2002). There are two major forms of
Aβ species found in vivo which include Aβ40 and Aβ42. The presence of two
additional hydrophobic resides on Aβ42 results in enhanced hydrophobicity and
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increased aggregation potential. Approximately 90% of secreted Aβ contains
the soluble residue (Aβ40) while only 10% of the total Aβ is comprised of Aβ42
(Price, Tanzi et al. 1998). Aβ42 becomes fibrillar, displays a beta sheet
conformation and is most often associated with diffuse plaques. Aβ40 is more
consistently seen in the blood vasculature and is involved in the development of
cerebral amyloid angiopathy (CAA) (Weiner and Frenkel 2006).
The accumulation of Aβ42 in the brain of AD patients is closely
associated with neurodegeneration. The identification of a number of mutations
in the APP gene has linked Aβ to the pathological development of AD.
Ultimately, these mutations have all been shown to increase the production of
Aβ42 in the brain (Selkoe 2001).

PRESENILIN STRUCTURE, FUNCTION, AND METABOLISM
PS1 and PS2 are homologous membrane proteins. The normal
physiological functions of the presenilins are unknown but it is thought that they
are involved in intracellular sorting or transport as indicated by their structure.
PS1 and PS2 are located in the ER and cis-golgi compartments of the cell and
are cleaved by a protease known as presenilinase, generating a 30 kDa Nterminal fragment (NTF) and a 20 kDa CTF (Turner, O'Connor et al. 2003).
Presenilin forms the active site of the γ secretase complex and is involved in the
production of Aβ (Spires and Hyman 2005). More than 75 missense mutations
in the PS1 gene and three in the PS2 gene have been found, and these FAD
mutations cause an increased production of Aβ42 (Hardy and Selkoe 2002).
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The genes for PS1 and PS2 are located on chromosomes 14 and 1,
respectively, and mutations in the presenilin genes appear to be responsible for
AD in certain families, with patients experiencing symptoms starting in their 40s
or 50s. The lack of presenilins has been found to reduce Aβ production, while
increasing the amounts of α and β secretase cleaved products. Furthermore,
mutations in presenilins affect the γ secretase cleavage site, increasing the
amount of Aβ42 produced. PS1 mutations cause the earliest and most
aggressive form of AD commonly leading to onset of symptoms before the age
of 50 (Jellinger and Bancher 1996).
In summary, each of the three genes identified are all associated with an
increased Aβ42 production or its enhanced deposition in the brain. These data
support the amyloid cascade hypothesis which states that missense mutations
in APP, PS1, or PS2 genes lead to an increased accumulation of Aβ42,
resulting in activated microglia, the release of neurotoxic species, and oxidative
stress which ultimately leads to the neuronal death seen in AD.

TRANSGENIC MOUSE MODELS OF Aß AMYLOIDOGENESIS
With the knowledge that Aβ plays a critical role in the development of
Alzheimer’s disease, several groups have created transgenic mice that
pathologically develop Aβ deposits similar to those found in human brains. Agedependent increases in learning deficits were also observed. The first transgenic
mouse model to show amyloid deposits was developed by Games and
colleagues in 1995 (Games, Adams et al. 1995). This model known as the
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PDAPP model was created using a platelet derived growth factor (PDGF) β-chain
promoter and a human APP mini gene containing the APP 717V Æ F mutation in
an APP cDNA with portions of intronic sequences allowing for alternative
splicing. These mice began to deposit amyloid in the hippocampus, corpus
collosum and cerebral cortex at approximately six to nine months of age. The
majority of plaques were surrounded by GFAP positive reactive astrocytes,
activated microglia and distorted neurites. Plaque density appeared to increase
with age in these transgenic mice as it does in humans, suggesting that
progressive Aβ deposition exceeds clearance as is proposed for AD. There were
no neurofibrillary tangles observed as well as no significant neuronal loss. It was
noted that PDAPP mice were impaired in a novel spatial memory task in an agedependent manner that correlated with the increases in plaque density (Chen,
Chen et al. 2000).
Another transgenic mouse model of AD with similar phenotype findings
was reported by Hsiao and her colleagues (Hsiao, Chapman et al. 1996). This
model termed Tg2576 or APPSW expresses the Swedish mutation of APP, the
695 amino acid form of human APP containing the K670N/M671L FAD mutation,
placed under the control of the hamster prion gene promoter. At 9-11 months of
age, Aβ deposition is observed in numerous brain regions.

However

neurofibrillary tangles are not observed. It is well documented that this mutation
causes increases in Aβ42 and Aβ40 (Scheuner, Eckman et al. 1996).

As

Tg2576 mice age, classic neuritic plaques with Congo red-positive amyloid cores
appear that are similar to those seen in AD (Irizarry, McNamara et al. 1997). In
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addition, Tg2576 mice develop age- dependent behavioral deficits on several
memory tests including the Y maze, T maze and Morris water maze testing
despite the fact that no significant neuronal loss is observed (Hsiao, Chapman et
al. 1996; Chapman, White et al. 1999). The TgCRND8 mouse model contains an
APP-695-cDNA with both the K670N/M671L and V717F mutations under the
control of the prion gene promoter (Chishti, Yang et al. 2001). The APP
transgene is expressed at a fivefold higher level than endogenous APP and Aβ
deposits are observed as early as three months of age.
Mice transgenic for the human APP gene (Hsiao, Chapman et al. 1996)
and the PS1 gene (Duff, Eckman et al. 1996) were crossed to produce a doubly
transgenic mouse presenting accelerated amyloid pathology (Holcomb, Gordon
et al. 1998). In the double transgenic mouse model, the diffuse deposits are
primarily composed of Aβ42, while the compact deposits and the vascular Aβ are
primarily composed of Aβ40. Double transgenic APP+PS1 mice deposit
increased amounts of the Aβ peptide in the cerebral cortex and hippocampus.
Compared to the single transgenic Tg2576 or PS1 mutant mice, the APP+PS1
model displays increased GFAP reactive astrocytes, activated microglia and
dystrophic neurites (Gordon, Holcomb et al. 2002). Neurofibrillary tangles are
also absent in this mouse model as seen in the other previous models. The
APP+PS1 mouse model demonstrates memory impairments in the Y maze and
radial arm water maze when compared to the non-transgenic mice (Holcomb,
Gordon et al. 1998).
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A triple transgenic model of AD (3xTg-AD) has recently been developed
that carries three Alzheimer’s disease relevant genetic mutations: a human
Presenilin M146V knock in mutation (PS1M146V), human amyloid precursor
protein Swedish mutation (APPswe), and the human tauP301L mutation (Oddo,
Caccamo et al. 2003). These mice develop plaques and tangle pathology in the
cerebral cortex, hippocampus and amygdala, which parallels the pathology seen
in AD patients. The development of tau pathology and Aβ deposition
simultaneously might allow this mouse model to give researchers a better insight
to therapeutically treating the disease.
Although none of the transgenic models of AD develop all of the
neuropathological features of the disease, these transgenic mouse models have
already provided important insights into the pathogenesis of the disease (Hock
and Lamb 2001). The correlation between cognitive decline and increases in
amyloid plaque deposition and location emulate those seen in the human
disease. Therefore, despite limitations, AD transgenic mice are a valuable model
for understanding the role of amyloid deposition in AD and will aid in the
development of immunotherapy for the treatment of this disease.

INFLAMMATION AND ALZHEIMER’S DISEASE
The process of aging and AD is intimately associated with microglial
activation, increased production of cytokines, reactive oxygen species and
neuronal deficits. Inflammation of the CNS may be the result of both innate and
adaptive immune responses. When 5 and 30 month old non transgenic mice
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were compared, it was observed that there was an increase in the expression of
many inflammatory and stress genes in the aged mice, including complement
factors, microglial activation markers, cyclophilin and heat shock proteins,
demonstrating a change in the inflammatory process with age (Lee, Weindruch et
al. 2000).
Evidence from studies with post mortem brain tissues and transgenic
mouse models of AD implicate microglial activation as a key process in dictating
the inflammatory responses seen in AD. Microglia, the resident macrophages of
the CNS, comprise about 12% of the cells in the CNS and participate in activities
such as phagocytosis, antigen presentation, production and release of cytokines,
complement components, reactive oxygen species as well as neurotrophins
(Minagar, Shapshak et al. 2002). Microglia are reactive not only in response to
trauma and injury, but also play an important role in sensing small changes in the
brain homeostasis which often precede that of pathological damage (Kreutzberg
1996). Found throughout the CNS parenchyma, microglial activation is
characteristic of many CNS diseases including, stroke, multiple sclerosis, AD,
and AIDS dementia (Flaris, Densmore et al. 1993; McGeer, Kawamata et al.
1993; Shrikant and Benveniste 1996; Sriram and Rodriguez 1997).
Microglia associated with Aβ plaques have an increased expression of
many inflammatory markers, including IL-1, IL-6, TNFα, MIP-1 and MCP-1.
Microglia express cell surface receptors required for interaction with different
types of immune cells as well as Aβ. These receptors include MHC I and II which
are needed in antigen presentation, the complement receptors CD11a, b, and c,
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and Fc receptors (Huang, Han et al. 2000).

While microglial activation has

traditionally been viewed as adverse, recent data suggests that microglia may
exert beneficial effects in AD as well (Wyss-Coray and Mucke 2002). Microglia in
cell culture have been shown to ingest and phagocytose Aβ and the presence of
microglia encompassing Aβ deposits may imply that

microglia

are

phagocytosing amyloid in an attempt to remove Aβ plaques (Wyss-Coray,
McConlogue et al. 2001). Recent observations with brain sections from both APP
transgenic mice and AD patients indicate that Fc-R mediated phagocytosis by
activated microglia may be implicated in the removal of antibody- opsonized Aβ
plaques (Schenk and Yednock 2002). Astroglial overproduction of TGF-β as well
as intracerebral injections of LPS have both demonstrated a decrease in Aβ
plaque load in vitro and in vivo (DiCarlo, Wilcock et al. 2001; Wyss-Coray,
McConlogue et al. 2001).
The lack of knowledge concerning the role of the inflammatory reaction in
AD makes it imperative that we understand the role of the innate and adaptive
immune response within the context of the development of AD. Microglial cells
may ultimately play a key role in protecting against or resolving Alzheimer-like
pathology. Changes in microglial activation states that increase their ability to
clear Aβ or adjust their response to Aβ may lead to a powerful therapeutic
treatment for AD (Schenk and Yednock 2002).
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MCP-1
MCP-1 belongs to the C-C family of chemokines and acts as a
chemoattractant for monocytes, activated T cells, basophils and NK cells. MCP-1
binds solely to CCR2, a seven transmembrane spanning protein that functions
through G-protein coupled receptors (Izikson, Klein et al. 2002). MCP-1 is likely
to be essential in this recruitment of bone marrow derived cells because the
release of this chemokine is the key mechanism for the chemoattraction of
monocytes. MCP-1 has been found immunohistochemically in mature, but not in
immature senile plaques and in reactive microglia of brain tissues from patients
with AD. In an adult Japanese population, MCP-1 levels in serum were
significantly increased from patients that demonstrated MCI and early AD, but not
in late stage AD cases. Galimberti et al (2006) hypothesized that increases in
MCP-1 were highest during a transitional state between mild cognitive decline
and the development of AD, and that MCP-1 might be serving a neuroprotective
effect by signaling to microglial cells to remove Aβ plaques (Galimberti, Fenoglio
et al. 2006). In addition, many groups have demonstrated that the injection of
leukocyte chemoattractant α or β chemokines into the mouse CNS can increase
the process of leukocyte migration (Bell, Taub et al. 1996; Stamatovic, Shakui et
al. 2005).

MONOCYTES
Monocytes are blood- derived leukocytes that develop in the bone
marrow, are released into the blood stream, and migrate into the brain and
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various other organs (Gordon and Taylor 2005). This process occurs not only
during development but continues throughout life (Wyss-Coray and Mucke 2002).
Monocytes are defined as blood mononuclear cells with bean- shaped nuclei,
expression of CD11b, CD11c, and CD14 in humans and CD11b and F4/80 in
mice, and represent about 5-10% of peripheral blood leukocytes. The total
leukocyte population in mice is approximately 106 cells, which equates to about 6
x 104 circulating monocytes per ml of mouse blood (Tacke and Randolph 2006).
Monocytes are components of the mononuclear phagocyte system which is
comprised of liver Kupffer cells, lung alveolar macrophages, peritoneal
macrophages, brain microglia, skin dendritic cells and bone osteoclasts. Under
steady state conditions in the mouse, about ½ of the circulating monocytes leave
the blood stream each day, where these cells enter into different tissues of the
body. Dying monocytes are destroyed in the spleen (Muller 2001). The life
span of monocytes is still under debate, but it is thought that the half life of
monocytes in blood is relatively short: about three days in humans and one day
in mice (Muller 2001). The short half life of monocytes in the blood has led to the
idea that these cells may be continuously replenished in order to preserve tissue
homeostasis and during times of an innate or adaptive immune response (Tacke,
Ginhoux et al. 2006). In mice responding to an inflammatory challenge, the
number of monocytes leaving the circulation per day is at least double.
As with other immune cells, the immune function and differentiation of
monocytes rely on communication with other cells through cell surface proteins.
The LFA-1 integrin (Leukocyte function-associated molecule 1) is composed of
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two subunits, CD11a and CD18 and is involved in monocyte adhesion. Mac-1 is
composed of the subunits CD11b and CD18 and is induced during inflammation.
PECAM-1 mediates the migration of monocytes and other immune cells into
inflamed tissues through interaction with vascular endothelial cells. VLA-4 is
another integrin that plays a role in adhesion through interaction with VCAM-1 or
intercellular adhesion molecule 1 (ICAM-1). Once the monocyte is tightly bound,
it then migrates between endothelial cells in response to MCP-1 (Gordon and
Taylor 2005; Tacke, Ginhoux et al. 2006; Tacke and Randolph 2006).
Peripheral blood monocytes display morophological heterogeneity in size,
granularity, and nuclear morphology. The initial criteria used to differentiate
monocytes from other leukocyte types include mononuclearity, high expression
of CD11b/Mac-1, high phagocytic capacity and the ability to develop into
macrophages upon stimulation with M-CSF (Tacke and Randolph 2006).
Monocytes can be classified into two groups: a short- lived inflammatory group
which homes to tissue during times of damage, and a resident group that
functions in the preservation of tissue homeostasis. In order to characterize
peripheral blood monocytes, various groups demonstrated the differential
expression of CD14 and CD16 monocytes in human blood (Lagasse and
Weissman 1996; Sunderkotter, Nikolic et al. 2004). These populations can be
defined into two major subsets: the classical CD14high CD16- monocytes which
express CCR2 and the nonclassical CD14low CD16+ monocytes which have
higher expression of MHCII, CCR5 and CD32 and resemble mature tissue
macrophages. Other groups have also identified that differential expression of
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markers

are

present

in

mouse

monocyte

populations.

These

studies

demonstrated that CCR2+CD62L+Cx3CR1+ or Ly6C+ or Gr-1 high mouse
monocytes correspond to CD14low CD16+ classic human monocytes which
seem to be migrate to non inflamaed sites. CCR2+Cx3CR1low or Ly6C-/low or
Gr-1 low correspond to CD14highCD16- human monocytes which seem to be
recruited to inflamed peripheral sites through recognition of CCL2/MCP-1
(Geissmann, Jung et al. 2003; Tacke, Ginhoux et al. 2006; Tacke and Randolph
2006). The identification of various subsets of monocytes has allowed
researchers to address the in vivo relevance of human monocytes by studying
mouse monocytes.
Inflammation, trauma and immune stimuli all cause an increased
recruitment of monocytes to peripheral tissues, aiding in host defense and tissue
repair (Taylor, Martinez-Pomares et al. 2005). The commonalities between
mouse and human monocyte subsets confirm a conserved system between
species (Gordon and Taylor 2005). Increased technical skill in isolating monocyte
subsets, as well a better understanding of monocyte antigen composition will
hopefully aid in a better understanding of the various physiological roles the
monocytic lineage plays.

MONOCYTE RECRUITMENT IN APP TRANSGENIC MICE
The importance of the peripheral immune system in the development of
AD pathology remains debatable. However, these pathological changes are
consistently seen to be connected with an inflammatory response involving
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microglia and astrocytes (Akiyama, Barger et al. 2000). In vitro studies have
shown the potential for Aβ to stimulate the production of cytokines, chemokines
and inflammatory mediators from human microglia. These signals may be able to
recruit peripheral immune cells into the brains of AD patients (McGeer and
McGeer 2001; Rogers and Lue 2001). However, the lack of a single definitive
marker to label monocytes makes it difficult to distinguish invading cells from
resident brain microglia (Guillemin and Brew 2004).
It is known that microglia cells are found associated with senile plaques in
humans (Haga, Akai et al. 1989; Itagaki, McGeer et al. 1989) as well is in
transgenic mice that develop amyloid (Perlmutter, Scott et al. 1992; Sheng, Mrak
et al. 1997; Wegiel, Wang et al. 2001; Wegiel, Imaki et al. 2003). One approach
used to track bone marrow derived cells (BMDCs) within the CNS uses bone
marrow chimeras, whose endogenous hematopoietic systems have been
destroyed by irradiation, then replenished with genetically tagged bone marrow
obtained from transgenic donors. By studying these transplantation models it has
been estimated about 20-40% of adult microglia undergo continuous turnover
from BMDCs in adulthood (Kennedy and Abkowitz 1997; Hess, Abe et al. 2004).
These observations have provided the basis for work aimed at using autologous
bone marrow to deliver therapeutic genes to damaged regions of the CNS
(Makar, Trisler et al. 2004). Previous studies have demonstrated engraftment of
marrow derived cells within the CNS, primarily as microglial cells (Priller, Flugel
et al. 2001; Vallieres and Sawchenko 2003; Simard, Soulet et al. 2006). Malm
and colleagues showed that overexpression of the mutant human APP+PS1
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genes in the AD mouse model resulted in an increased migration of bone marrow
derived monocytes into the brain during the progression of AD pathology. They
demonstrated a 17- fold higher increase in the number of bone marrow derived
cells associated with Aβ deposits in mice transplanted before the development of
AD pathology compared to aged AD mice transplanted after Aβ deposition
(Malm, Koistinaho et al. 2005). Simard’s group studied the migration of bone
marrow transplanted cells in different aged irradiated APP23 mice and found that
bone marrow cells could cross the BBB and that approximately 20% of the cells
were associated with congophilic plaques. Simard’s group also injected different
isoforms of Aβ and found that Aβ 40 and 42, but not Aβ 31 and 57 isoforms,
were capable of inducing the infiltration of blood-derived monocytes as well as
activation of inflammatory genes such as TLR-2, IL-1β and MCP-1 (Simard,
Soulet et al. 2006). Wegiel and colleagues (Wegiel, Imaki et al. 2003) found that
most of the Aβ plaques in APPSwe mice were associated with blood vessels and
that monocytes are found at the interface between the blood vessels and the Aβ
plaques, supporting the hypothesis that the recruitment of bone marrow derived
monocytes into the brain occurs during the development of Aβ deposits.
Studies implicating the homing of monocytes to regions of CNS damage
have led to the idea that these cells could be used to deliver therapeutic genes to
the brain (Kokovay and Cunningham 2005). Bone marrow monocytes could
serve as an alternative source to stem cells, because they are safe, readily
available and ethically acceptable source for cell and gene therapy (Vallieres and
Sawchenko 2003). Microglial cells are considered a promising therapeutic target
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in AD because of their potential role in Aβ plaque evolution and even
phagocytosis of Aβ deposits. At least some of these Aβ associated microglial
cells are produced in the bone marrow and circulate in the blood prior to and
during the development of AD (Malm, Koistinaho et al. 2005). The signal that
causes the infiltration of blood derived microglia in this model of AD has yet to be
determined. Moreover the ability of different β-amyloid isoforms to recruit and
activate microglial cells in vivo is still under debate. Understanding the relative
contribution of these cells to the pathological conditions seen in AD will be
important when designing future immunotherapies that specifically target Aβ
deposits in the brain.

GENE THERAPY
The ability to correct a disease phenotype in vivo through the use of a
gene as a pharmacological agent has been termed gene therapy (Friedmann
1989). This type of therapy is based on the notion that the disease phenotype
can be corrected either through the modification of the resident mutant gene or
through the introduction of new genetic information into the defective cells or
organs in vivo. The main limiting step of treating CNS disorders is the blood brain
barrier which limits the influx of cells into the brain parenchyma (Priller, Flugel et
al. 2001). The BBB is crucial for the brain to maintain homeostasis, but presents
a major obstacle when developing gene therapy treatments for CNS diseases.
Presently, CNS gene transfer studies have relied on direct injections of cells or
vectors into the brain (Eglitis and Mezey 1997). Transplantation studies have
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been performed in different neurodegenerative diseases and have even gone to
clinical trial in Parkinson’s disease. However, the ability of these transplanted
cells to survive is low, with only about 5-10% of the transplanted embryonic
neurons surviving. Also, in these early studies the damage resulting from drilling
holes into the skull or the introduction of a catheter to allow for cell infusion all
lead to the potential for high risk. Thus, noninvasive gene therapy methods are
needed.
Previous studies have demonstrated engraftment of marrow derived cells
within the CNS (Priller, Flugel et al. 2001; Vallieres and Sawchenko 2003;
Simard and Rivest 2004). These observations have provided the basis for work
aimed at using autologous bone marrow to deliver therapeutic genes to damaged
regions of the CNS (Park, Eglitis et al. 2001; Makar, Wilt et al. 2002; Makar,
Trisler et al. 2004). Bone marrow cells have been used as a delivery system to
express transgenes in the CNS such as glial derived neurotrophic factor and
interferon-beta (Makar, Trisler et al. 2004). However, much of our knowledge
about bone marrow derived microglia in the normal and injured CNS has been
generated by the usage of lethally irradiated mice in which the population
dynamics of cells in the brain and in the bone marrow may differ from that of a
normal, non-irradiated mouse (Gaugler, Squiban et al. 2001).

It has been

suggested that it may be possible to use genetically modified monocytes to carry
exogenous genes of interest into the brain or other organs for the purposes of
gene therapy. The evaluation of this novel approach to CNS gene therapy will
require considerable preclinical analysis, but a critical first step lies in the
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development of efficient methods for ex vivo gene transfer into primary mouse
monocytes. Experiments using retroviral and lentiviral vectors have already
established the ability of gene engineered hematopoietic stem cells to investigate
the nature and fate of monocytes under physiological and pathophysiological
conditions in the brain (Mezey and Chandross 2000; Priller, Flugel et al. 2001;
Djukic, Mildner et al. 2006) With growing interest in the use of monocytes as a
novel cellular vehicle for gene therapy in the CNS, it is of interest and importance
to develop optimized in vitro transfection techniques for genetic modification of
primary monocytes ex vivo.

NEPRILYSIN
One contributing and potentially causal factor in the accumulation of Aβ in
late onset AD is the decrease in proteases that normally clear soluble Aβ. In
general Aβ levels are determined by the balance between Aβ production and
removal. Thus, even small changes in the rate of proteolytic degradation of Aβ
peptides could contribute to AD. Several Aβ degrading proteases have been
identified by their ability to cleave Aβ, including Neprilysin (NEP), Insulin
Degrading Enzyme (IDE), Endothelin Converting Enzyme (ECE), Matrix
Metalloproteinase-9 (MMP-9) and Matrix Metalloproteinase-2 (MMP-2). Each
protease appears to have distinct cleavage sites and generates variable Aβ
fragments. However, only NEP, IDE and ECE have been reported to affect Aβ
levels in the brains of experimental animal models. Overexpression of IDE or
NEP in AD -related animal models has shown a decrease in levels of Aβ1-42,
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confirming the importance of these enzymes in regulating Aβ turnover in vivo
(Leissring, Farris et al. 2003; Leissring, Lu et al. 2003).
Neprilysin (NEP) is a type II membrane metalloendopeptidase comprised
of approximately 750 residues. NEP is also referred to as enkephalinase,
common

acute

lymphoblastic

leukemia

antigen

(CALLA)

and

neutral

endopeptidase and can catalyze the hydrolysis of specific signaling peptides in
order to inactivate and degrade their signal (Turner, Fisk et al. 2004). Peptides
that NEP targets include bradykinin, glucagon, and neuropeptides such as
neurotensin and enkephalin (Johnson, Stevenson et al. 1999; Sakurada,
Sakurada et al. 2002). NEP is made of 3 parts: an N-terminal domain of 321
residues known as domain 1, a C-terminal domain of 286 residues known as
domain 2 and 4 linker fragments connecting domains 1 and 2. Domain 1 contains
the active site with a HExxH motif, a motif that is a common feature of many zinc
peptidases

(Turner, Fisk et al. 2004). NEP is strongly inhibited by

phosphoramidon (a protease inhibitor made by streptomyces), thiorphan, and
EDTA but can be reactivated by zinc (Roques 1993; Iwata, Mizukami et al.
2004). NEP is activated by cytokines, glucocorticoids, and protein kinase C and
is found in many different types of cells in the body such as the kidney, intestine,
lungs, CNS, neutrophils, fibroblasts, and epithelilal cells (Roques, Noble et al.
1993; Wang, Dickson et al. 2006).
Lentiviral overexpression of NEP in the brain has been shown to decrease
Aβ deposits in APP transgenic mice with significant plaque loads (Marr,
Rockenstein et al. 2003). Iwata et al (Iwata, Mizukami et al. 2004) showed that
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degradation of exogenously administered Aβ42 was decreased in NEP-deficient
mice when compared to nontransgenic controls. Additionally the endogenous
levels of Aβ40 and Aβ42 were significantly elevated in the brains of NEPknockout mice, validating that NEP is a physiologically relevant Aβ degrading
enzyme. Marr et al (Marr, Rockenstein et al. 2003) injected a lentiviral vector
expressing human NEP unilaterally into the hippocampus of APP transgenic
mice. One month later, amyloid burden was found to be significantly reduced on
the injected hemisphere and remaining plaques were notably smaller than those
found on the contralateral side(Turner, Fisk et al. 2004). The effect of NEP gene
transfer via AAV vectors was examined in APP transgenic mice by Iwata et al, as
well as in our lab (Iwata, Mizukami et al. 2004; Carty, Wilcock et al. 2006), both
demonstrating that NEP gene transfer can reduce amyloid deposition in aged
transgenic mice. These results show that even fairly small up- regulation of NEP
activity may be sufficient to reduce Aβ accumulation in the brain.
Neprilysin expression in the brain has been shown to decrease during the
aging process and in the early stages of AD progression (Mueller-Steiner, Zhou
et al. 2006). Recent in vitro and in vivo studies demonstrate that the up regulation
of Aβ degrading enzymes can significantly reduce the development of the Aβ
peptide (Eckman and Eckman 2005). Gene therapy may be a key therapeutic
treatment allowing for an increased expression of Aβ degrading proteases in the
brain. Identification of a method to selectively upregulate brain neprilysin activity
may provide a new therapeutic potential (Saito, Iwata et al. 2005). The ability of
monocytes to enter into the brain in response to inflammatory signals and
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associate with amyloid plaques doubled with the fact that they are easy to obtain
and can be genetically altered makes monocytes an ideal cell choice (Priller,
Flugel et al. 2001) . Putting monocytes together with an amyloid degrading
enzyme such as neprilysin offers a powerful novel therapeutic tool for the
treatment of Alzheimer’s disease (Stalder, Ermini et al. 2005).
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ABSTRACT
The recruitment of peripheral blood monocytes into the brain during the
development of amyloid pathology is poorly understood. Previous work by other
groups as well as our own has shown that bone marrow derived monocytes have
the ability to migrate to the brain and associate with amyloid deposits in the AD
transgenic mouse model. Circulating monocytes have only been studied to a
limited extent in the mouse, due in part to the limited availability of cells and the
lack of definitive marker to identify this cell type. Consequently, the life span and
migration abilities of these cells remain uncertain. To determine the time course
of monocyte recruitment into the brain during the neurodegenerative damage
characteristic of Alzheimer’s disease, we used transplanted GFP labeled bone
marrow monocytes to characterize the kinetics that peripheral monocytes display
once injected into the circulation. We first determined the half life of bone marrow
derived monocytes after one injection into the peripheral circulation, and found
this time to be 1.5 hours post injection. We also determined where these cells
migrated following their exit from the blood stream. Our data indicate that there is
a recruitment of these monocytes to the spleen, lungs, liver and brain. Through
stereological and flow cytometry analyses, we also show that APP+PS1 mice
have significantly more recruitment of monocytes to the brain in areas of plaque
deposition compared to control nontransgenic mice.
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INTRODUCTION
Increasing evidence suggests that the accumulation of amyloid plaques,
composed primarily of the amyloid beta protein (Aβ), is a common
histopathological feature in Alzheimer’s disease (AD). Aβ may play a critical role
in disease progression (Hardy and Selkoe 2002). Although microglial cells
respond and demonstrate morphological changes when exposed to Aβ, (Bard et
al., 2000; DiCarlo et al., 2001; Wyss-Coray et al., 2001; Wilcock et al., 2003). the
role the peripheral immune system in the disease process remains debatable.
However, these pathological changes are consistently seen to be connected with
an inflammatory response involving microglia and astrocytes (Akiyama et al.,
2000; Ueda et al., 2004; Nagaoka et al., 2000). In vitro studies have shown the
potential for Aβ to stimulate the production of cytokines, chemokines and
inflammatory mediators from human microglia. These signals may be able to
recruit peripheral immune cells into the brains of AD patients (McGeer and
McGeer 2001; Rogers and Leu 2001).

It is well known that microglia cells are

found associated with senile plaques in humans (Haga et al., 1989; Itagaki et al.,
1989) as well is in transgenic mice that develop amyloid (Perlmutter et al., 1992;
Sheng et al., 1997; Weigel et al., 2001; Weigel et al., 2003). At least some of
these Aβ associated microglial cells are produced in the BM and circulate in the
blood prior to and during the development of AD (Malm et al., 2005). The signal
that causes the infiltration of blood derived microglia in this model of AD has yet
to be determined. Moreover the ability of different β-amyloid isoforms to recruit
and activate microglial cells in vivo is still under debate. Understanding the
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relative contribution of these cells to the pathological conditions seen in AD will
be important when designing future immunotherapies that specifically target Aβ
deposits in the brain.
Furthermore, monocyte derived and resident CNS microglia are practically
identical on the basis of current immunophenotypic markers. The lack of a single
defining marker to distinguish the invading monocytes/macrophages from
resident and activated microglia has made the study of the peripheral system’s
involvement in the CNS challenging. Their isolation therefore presents a
challenge and accounts for the current scarcity of kinetic data on pure monocytes
populations in AD. Previous studies on the turnover of monocytes in the
circulation used autoradiography to detect cells labeled at various times using an
infusion of [3H]thymidine, which labels the DNA of cells in S-phase. (Van Furth et
al 1970) However since we are now able to track the migration of GFP labeled
cells, it is possible to identify the location from which these cells are originating.
The migratory route monocytes take once leaving the bone marrow is currently
unclear, but previous work has suggested that hematopoietic cells may migrate
into the brain parenchyma to give rise to microglia (Massengale et al 2005, Priller
et al., 2001, Vallieres et al., 2003). One drawback of all of these studies,
however, was the use of lethal whole body irradiation prior to bone marrow
transplantation, which could have induced neuroinflammation, altered the state of
the blood brain barrier, and artefactually promoted peripheral immune cell entry.
In the present study, we used transplanted GFP labeled bone marrow
monocytes to discriminate peripheral monocytes from intrinsic brain microglia.
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We used these identifiable donor cells to characterize the kinetics that peripheral
monocytes display once injected into the circulation. We first determined the half
life of bone marrow derived monocytes in the peripheral circulation. Our data
indicate that there is a recruitment of these monocytes into the spleen, lungs,
liver and brain from circulation. Through stereological and flow analyses, we also
show that APP+PS1 mice have more recruitment of monocytes to the brain in
areas of plaque deposition compared to control non transgenic mice.

MATERIALS AND METHODS
Animals
16 month old double transgenic APP+PS1 mice that are a cross between the
mAPP transgenic line Tg2576 (Hsiao, Chapman et al. 1996) and the mPS1
transgenic line 5.1 (Duff, Eckman et al, 1996) and nontransgenic littermates were
used. The GFP transgenic mouse model used for bone marrow donors were
C57BL/6-Tg(UBC-GFP)30Scha/J [Jackson Laboratory, Bar Harbor, ME; Stock
#004353]. These transgenic mice express the enhanced green fluorescent
protein (GFP) under the direction of the human ubiquitin C promoter. All mice
were bred and maintained in our animal facility according to institutional
guidelines.
Adoptive Transfer of Monocytes
Transgenic GFP mice were overdosed with pentobarbital. The femurs and tibias
were removed aseptically and bone marrow was flushed from the bone using a
25G 5/8 gage needle attached to a syringe. Cells were collected by centrifugation
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for 5 minutes at 300xg (4°C). CD11b+ cells were separated using
immunomagnetic cell depletion using MACS technology (Miltenyi Biotec, Auburn
CA). 5 X 106 freshly isolated CD11b+, GFP+ cells were then resuspended in 100
µl saline and injected into the left heart ventricle.

Blood
1 mL of blood was drawn from each mouse via cardiac puncture. 10 ml of RBC
lysis buffer was immediately added to the blood and incubated for 5 minutes. To
stop the reaction, 30 ml of 1xPBS was added, and the cells were centrifuged at
300xg at 4°C for 10 minutes. Cells were resuspended in PBS and taken for flow
cytometry analysis. GFP+ and total cell numbers in the blood were analyzed at 1
minute, 30 minutes, 2 hours, 4 hours, 6 hours, and 24 hours following cell
injection.

Tissue Collection and Histochemical Procedures
On the day of sacrifice, mice were overdosed with pentobarbital (100mg/kg). The
brain, spleen, liver and lung were removed, bisected sagittally and the left half
was immersed in freshly prepared 4% paraformaldehyde in 100 mM PO4 buffer
(pH 7.4). The organs were postfixed in paraformaldehyde for 24 hours. The
brain, liver and spleen tissue were cryoprotected in a series of sucrose solutions,
frozen, sectioned in the horizontal or transverse plane at 25 µm using a sliding
microtome and stored at 4°C in Dulbecco’s phosphate buffered saline for
immunocytochemistry and histology. The lung tissue was paraffin embedded
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before being sectioned using a rotary microtome. One-half of each organ was
digested as described (Cardona et al 2006). Single-cell suspensions were
analyzed by flow cytometry.
Immunohistochemistry was performed on free floating sections as described in
detail previously (Gordon et al, 1997). A series of 8 sections spaced
approximately 600μm apart were incubated with primary antibody overnight at
4°C, then incubated in the biotinylated secondary antibody (2h) followed by
streptavidin-peroxidase.

Peroxidase

reactions

consist

of

1.4

mM

diaminobenzidine with 0.03% hydrogen peroxide in PBS for exactly 5 minutes.
Single and multiple immunofluorescent labeling: after incubation with the primary
antibody, the free floating sections were then incubated for 2 hours with the
appropriate fluorophore coupled secondary antibody. As secondary antibodies,
goat IgG coupled to AlexaFluor 594 (1:1500), AlexaFluor 488 (1:1500) (Molecular
Probes, Eugene, OR) were used. Sections were rinsed in Dulbecco’s PBS and
coverslipped with VECTASHIELD Mounting Medium with DAPI.

Image and Flow Cytometry Analysis
GFP fluorescence, immunohistochemistry and Congo red staining were
quantified with Image Pro Plus (Media Cybernetics) image software. All values
obtained from a single mouse were averaged together to represent a single value
for that animal. Statistical analysis was performed using ANOVA followed by
Fischer’s LSD post hoc means comparison test (Statview software from SAS).
For flow cytometry cells were analyzed on a FACSCalibur cytometer or LSR

33

cytometer (Becton Dickinson, Mountain View, CA) using CellQuest software
(Becton Dickinson).

Stereology
N = (Number of cells counted) x (1/ ssf) x ( 1/asf) x (1/tsf)
ssf = the sampling fraction (i.e. a 1/6 series or 1/17). The fraction of the total
samples used
asf = area sampling fraction ( this is going to be 1 since you counted everything).
Tsf = thickness sampling fraction (you will have to measure with a z axis
encoder)
M.J. West and H.J.G. Gundersen, Unbiased stereological estimation of the
number of neurons in the human hippocampus. J. Comp. Neurol. 296 (1990)

RESULTS
Injected monocytes have a short half life in circulation: In order to track the
migration of injected monocytes through the blood stream following a single
injection of 5 million monocytes, GFP mice were used as cell donors. These cells
were injected into the left ventricle and the mice were analyzed at 6 time points
following the injection. Using flow cytometry, we were able to identify the GFP
monocytes in the blood and determine their relative numbers at each time point
(Figure 1). Injected monocytes spent very little time in the blood stream following
injection, with a half life of 1.5 hours. By 24 hours, we were not able to find any
GFP labeled monocytes in the circulation.
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Monocytes can be found in the brain, liver, lung and spleen up to a week
after cell injection: To determine the number of GFP bone marrow derived cells
in spleen, liver, lung and the brains of APP+PS1 transgenic and nontransgenic
mice, cells were visualized using a florescent microscope and stereological
analysis (Figure 2A) or by flow cytometry (Figure 2B). Stereological analysis
detected a significant difference in recruitment in the liver, lung and spleens
between the nontransgenic and the APP+PS1 transgenic mice. While not
significant, these trends were also confirmed using flow cytometry analysis
(Figure 2B). This significant increase in the organs of the nontransgenic mice is
most likely due to the fact that the majority of the GFP+ monocytes in the APP+
PS1 were located in the brain. In the nontransgenic control mice, only a few cells
were seen in the brain and the few that were present were associated with the
blood vessels. The APP+PS1 mice however, recruited a significant number of
GFP positive cells to the brain following a single injection. These cells were found
mainly in the cortex and hippocampal locations, those regions with high amyloid
load. Stereological analysis revealed a 90 % increase for the transgenic mice
compared to the nontransgenic 24 hours after the injection. These results were
confirmed with flow cytometry, which confirmed a significant increase of 97 % in
GFP+ cell number in the brains of APP+PS1 mice.
Morphologically the GFP+ monocytes looked identical in the spleen, liver and
lung when compared between the two groups of mice as seen in Figure (3).
Fluorescent analysis also revealed an association of the GFP+ cells with brain
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amyloid deposits. The majority of these cells were ameboid in shape; however a
small percentage of the cells displayed short processes. It is important to note
that while some amyloid plaques were decorated with GFP+ cells, other
neighboring plaques completely lacked any association with GFP+ cells. The size
of the plaque did not seem to be a factor for the association with GFP positive
cells.
The residence time of these cells following their migration from the blood to the
various tissues also demonstrated a transient time course. The most number of
cells were observed at the shortest time point (1 day). Although the rate of
decline seemed to vary somewhat in different organs, by day 7, almost all of the
GFP+ monocytes were absent from each of the organs examined.

DISCUSSION
Although previous studies have demonstrated infiltration of GFP+
peripheral microglia following irradiation and bone marrow reconstitution, the
percent contribution of circulating monocytes to the microglial reaction in brains
has not been investigated. In this present study, we characterized the half life
and migration of bone marrow mouse monocytes in nonirradiated mice. To track
these monocytes, we utilized bone marrow monocytes from mice that express an
enhanced green fluorescent protein (GFP) under the direction of the human
ubiquitin C promoter into APP+PS1 and nontransgenic mice. We demonstrated
that monocytes have a short half life in blood circulation: 1.5 hours following a
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single injection. Ultimately these cells leave the circulation and enter a variety of
tissues including the lung, liver, spleen and the brain.
Despite considerable advances in understanding immune cell migration
into the CNS, the invasion of different immune cells is only understood in part.
Under non-inflammatory conditions, it has been reported that there are
approximately 3000 macrophages recruited to the brain of a normal mouse each
day (Larson et al 1992). While we did not see a significant recruitment of GFP+
monocytes in the brains of nontransgenic mice, we did demonstrate that an overexpression of AD linked mutant human APP and PS1 genes in mice triggers a
significant increase in migration of bone marrow derived monocytic cells into the
brain. These cells were able to access all regions of the brain and had a transient
lifespan, about 7 days, once in the CNS parenchyma. Although the percentage of
GFP+ monocytes was small compared to the endogenous microglia, the majority
of monocytes were located near and around amyloid plaques. These results
emphasize that there is an interaction occurring between the peripheral immune
system and cells in the CNS. It has been proposed that chemokines presented
by the vascular endothelium regulate influx of hematopoietic cells and direct their
fate from bone marrow to blood and tissues. However, with the presence of
inflammation, changes in the cellular composition of these sites increases the
emigration of bone marrow cells into the circulation (Rot A. and von Andrian,
2004; Tani et al., 1994; Pleiner et al., 1998). It has been hypothesized that many
of the signals that request cells to the brain are mediated by the release of pro
and anti-inflammatory cytokines. Cytokines such as IL-1β, TNF-α, and TGF-β are
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released from astrocytes and microglia during brain inflammation and can
intensify the expression of adhesion molecules and chemokines resulting in an
increased extravasation of leukocytes (Kim and de Vellis, 2005; Campbell et al.,
1998; Merrill and Murphy, 1997). MCP-1 is likely to play a role in the recruitment
of bone marrow derived cells, because the release of this chemokine by
endothelial cells is the key mechanism for the chemoattraction of cells of
monocytic lineage. This chemokine is rapidly synthesized by endothelial cells in
response to immune stimuli, which triggers monocyte recruitment and rolling prior
to their transmigration. MCP-1 is also reported to be increased in the brains of
amyloid-depositing transgenic mice (Simard et al 2006; Janelsins et al 2005). An
up regulation of ICAM-1 could also contribute to recruitment of immune cells from
the circulation. It is likely that monocytes express receptors for ICAM-1 on their
surface and endogenous brain microglia might signal to peripheral cells through
an up regulation of this adhesion molecule (Woiciechowsky et al., 2002; Merrill
and Beneveniste 1996).
Another important factor in the recruitment of monocytes is to determine
which population is recruited to the brain. In our study we isolated monocytes
from bone marrow using a magnetic cell separation kit that used CD11b as the
marker to isolate the cells. Many groups have recently identified two subsets of
CD11b monocytes: a resident and an inflammatory subset. The so called
inflammatory monocytes express the cell surface protein Ly6c(gr1+), the
chemokine receptor CCR2, and the adhesion molecule L-selectin. They are
selectively recruited to inflamed tissues and lymph nodes and also have the
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capability to differentiate into inflammatory dendritic cells. The second subset of
monocytes has been designated resident in mice because they are located in
both resting and inflamed tissues. This subset is defined by smaller size, high
expression of both the chemokine receptor CX3CR1 and LFA-1 integrin, and by
the lack of expression of Ly6c, CCR2 and L-selectin (Geissman et al., 2003;
Sunderkotter et al., 2004; Palframan et al., 2001). Resident and inflammatory
monocytes thus appear to be defined by distinct sets of adhesion molecules and
chemokine receptors, which suggests different modes of tissue trafficking.
However there are still important questions that need to be addressed when
profiling these monocytes. For example, do these monocytes leave the bone
marrow prepared to enter the tissues through the presence of a specific
receptor? Or is it the presence of an inflammatory stimulus that causes a switch
in these cells from a resident to inflammatory state? Also it will be important to
determine if there are distinct receptors that direct monocytes to specific organs
following emigration from the bone marrow. Answers to these fundamental
questions will be important to further understand the recruitment of each subset
in the presence of AD pathology in transgenic mice and to further specify the
exact population that migrates to the brain.
While it is well known that microglia cells are found associated with senile
plaques in humans(Haga et al., 1989; Itagaki et al., 1989) as well as in
transgenic mice that develop amyloid (Perlmutter et al., 1992; Sheng et al.,
1997); Weigel et al 2001; Weigel et al 2003) many groups have argued the origin
of the cells. However, recently studies have demonstrated engraftment of marrow
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derived cells within the CNS (Hess et al., 2004; McMahon et al., 2002; Simard
and Rivest, 2004; Yagi et al., 2004). Consistent with the data presented in this
study, Malm and colleagues showed that overexpression of the mutant human
APP+PS1 genes in the AD mouse model resulted in an increased migration of
bone marrow derived monocytes into the brain early in the progression of AD
pathology. They demonstrated a 17- fold higher increase in the number of bone
marrow derived cells associated with Aβ deposits in mice transplanted before the
development of AD pathology compared to aged AD mice transplanted after Aβ
deposition (Malm et al., 2005). Simard’s group studied the migration of BM
transplanted cells in different aged irradiated APP23 mice and found that bone
marrow cells could cross the BBB and that approximately 20% of the cells were
associated with congophilic plaques. Simard’s group also injected different
isoforms of Aβ and found that Aβ 40 and 42, but not Aβ 31 and 57 isoforms, were
capable of inducing the infiltration of blood-derived monocytes as well as
activation of inflammatory genes such as TLR-2, IL-1β and MCP-1 (Simard et al.,
2006). Wegiel and colleagues (Weigel et al., 2003) found that most of the Aβ
plaques in APPSwe mice were associated with blood vessels and that monocytes
were found at the interface between the blood vessels and the Aβ plaques,
supporting the hypothesis that the recruitment of BM derived monocytes into the
brain occurs during the development of Aβ deposits.
Studies implicating the homing of monocytes to regions of CNS damage
have led to the idea that these cells could be used to deliver therapeutic genes to
the brain (Kokovay and Cunningham, 2005). BM monocytes could serve as an
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alternative source to stem cells, because they are safe, readily available and
ethically acceptable source for cell and gene therapy (Vallieres and Sawchenko
2003). Microglial cells are considered a promising therapeutic target in AD
because of their potential role in Aβ plaque evolution and even phagocytosis of
Aβ deposits. At least some of these Aβ associated microglial cells are produced
in the BM and circulate in the blood prior to and during the development of AD
(Malm et al., 2005). The signal that causes the infiltration of blood derived
microglia in this model of AD has yet to be determined. Moreover the ability of
different β-amyloid isoforms to recruit and activate microglial cells in vivo is still
under debate. Understanding the relative contribution of these cells to the
pathological conditions seen in AD will be important when designing future
immunotherapies that specifically target Aβ deposits in the brain.
In summary, our data provide evidence that peripheral bone marrow
monocytes are actively recruited to the brains in AD transgenic mouse models.
Monocytes were localized near and around plaque pathology only in the
APP+PS1 transgenic mouse and not in the non transgenic mouse model.
Defining the contribution of monocytes to the neuroinflammatory response in AD
and other neurodegernative diseases may reveal new therapeutic targets or
gene delivery approaches. Monocytes represent a novel therapeutic vehicle for
delivering drug molecules or proteases to improve recovery and repair brain
damage for the treatment of AD.
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Figure 1: THE HALF LIFE OF INJECTED GFP+ MONOCYTES IN
CIRCULATION IS APPROXIMATELY 1.5 HOURS.
A single injection of 5 x 106 GFP bone marrow monocytes was made into the left
ventricle of the heart of nontransgenic mice. At the indicated time points, blood
was collected and the number of GFP+ monocytes in the blood was measured by

# GFP+ Monocyte in 1 mL blood x 106

flow cytometry (n=4 at each time point).
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Figure 2: MIGRATION OF GFP+ MONOCYTES TO ORGANS IN THE
PRESENCE AND ABSENCE OF ALZHEIMER-like PATHOLOGY
Recruitment of GFP+ bone marrow monocytes to tissues in nontransgenic and
APP+PS1 transgenic mice were compared. A single injection of 5 x 106 GFP+
bone marrow monocytes was made into the left ventricle of the heart, and blood
was collected 1, 3 and 7 days later. The number of monocytes present in each
organ was quantified using (A) stereology and (B) flow cytometry and is plotted
as the number of GFP monocytes / mg of tissue for each organ. * indicates
significant differences between APP+PS1 and non transgenic mice (P <0.05 by
t-test). (n=4 at each time point).
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Figure 3: GFP+ MONOCYTE ENTRY INTO TISSUE
Representative micrographs of GFP staining in the tissues indicated above each
panel. Scale bar = 25 µm.
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ABSTRACT
The accumulation of amyloid-β protein (Aβ) in Alzheimer’s disease (AD) is
a well known pathological event. Decreasing the production or increasing the
degradation of Aβ is therefore thought to serve as a potential therapeutic
intervention in AD. Recent in vitro and in vivo studies have suggested that certain
proteases may be involved in the catabolism of Aβ and defects in the
degradation of Aβ could contribute to AD disease progression. Additionally,
studies implicating the homing of monocytes to regions of CNS damage have led
to the idea that it may be possible to use genetically modified monocytes to carry
exogenous genes of interest into the brain or other organs for the purposes of
gene therapy. The evaluation of this new technique in CNS gene therapy will
warrant extensive preclinical investigation, but a crucial first step requires the
characterization and optimization of efficient ex vivo methods of gene transfer
into primary mouse monocytes.
As an approach to up regulate levels of these Aβ-degrading proteases in a
transgenic mouse model of amyloid deposition, we developed an ex vivo gene
therapy method utilizing bone marrow monocytes from mice transgenic for green
fluorescent protein (GFP) mice. These monocytes were transfected with a
construct directing expression of either a secreted neprilysin protein (NEP-S) or a
mutant form (NEP-M), which lacks any enzyme activity, into the brains of APP tg
mice. We found a significant reduction in both Aβ and Congo Red staining in the
NEP-S injected mice only. These results support the hypothesis that NEP plays a
role in Aβ clearance and that pairing monocytes together with an amyloid-
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degrading enzyme such as NEP offers a powerful novel therapeutic tool for the
treatment of Alzheimer’s disease.

INTRODUCTION
Alzheimer’s disease (AD) is the most common cause of senile dementia
and is characterized by the presence of amyloid plaques, neurofibrillary tangles,
neuron loss and gliosis. Many different studies have alluded to Aβ as a culprit in
AD disease progression because the 40-42 amino acid peptide is the major
component of amyloid deposits seen in postmortem AD pathology (Selkoe, 1999,
Gandy. S, 2005). Also, the genetic changes observed in the inherited forms of
AD have shown an increase in the assembly of Aβ or a mutation in the β amyloid
precursor protein from which Aβ is derived (Mills et al., 1999, Tanzi, and Bertram,
2005). Decreasing the production or increasing the degradation of Aβ is therefore
thought to serve as a potential therapeutic intervention in AD. However, while the
mechanisms for the production of Aβ have been studied at length, little is known
about the normal degradation processes of Aβ in the brain. Evidence from many
laboratories suggests that decreasing Aβ levels in brain tissue is a logical
approach to prevent or slow the development of AD (Qiu et al., 1997, Saido et
al., 1998, Mentlein et al., 1998).
Recent in vitro and in vivo studies have suggested that certain proteases
may be involved in the catabolism of Aβ, and that defects in the degradation of
Aβ might play a role in AD disease progression. Proteases that may be involved
in Aβ degradation include insulin degrading enzyme (IDE), endothelin converting
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enzyme (ECE), matrix metalloproteinase (MMP-9), and neprilysin (NEP) (Iwata et
al., 2000, Iwata et al, 2001, Eckman et al., 2001, McDermott et al 1997, Qiu et al
1998, Carvalho et al, 1997). Neprilysin (NEP) is a type II membrane
metalloendopeptidase comprised of approximately 750 residues, and can
catalyze the hydrolysis of specific signaling peptides in order to inactivate and
degrade their signal (Iwata et al., 2001). NEP is also referred to as
enkephalinase, common acute lymphoblastic leukemia antigen (CALLA) and
neutral endopeptidase. Peptides that NEP targets include bradykinin, glucagon,
neurotensin and enkephalin (Johnson et al., 1999; Sakurada et al., 2002). NEP is
a presynaptic membrane associated ectoenzme with an extracellular active site,
and it is involved in Aβ degradation at presynaptic sites (Iwata et al., 2004;
Fukami et al., 2002; Turner et al, 2004). Down regulation of NEP in the
hippocampus and cerebral cortex with aging (Iwata et al., 2002; Caccamo et al.,
2005) and during the early stages of AD development (Caccamo et al., 2005;
Yasojima et al., 2001) suggests a link between

NEP and AD etiology and

pathogenesis. In fact, over expression of NEP in transgenic mice has revealed a
decrease in the levels of Aβ, as well as an increase in the lifespan (Marr et al.,
2003, Leissring et al 2003).
Previous studies have demonstrated engraftment of marrow- derived cells
within the CNS (Priller et al. 2001; Vallieres and Sawchenko, 2003; Simard and
Rivest, 2004). Although the signal that causes the infiltration of marrow- derived
cells into the CNS remains to be determined, Aβ is one candidate because the
marrow-derived cells become localized around amyloid plaques. In addition, the
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ultimate fate of the marrow-derived cells is controversial as well. One hypothesis
is that they differentiate into microglia and play a potential role in Aβ plaque
evolution. These observations have provided the basis for work aimed at using
autologous bone marrow-derived cells to deliver therapeutic genes to damaged
regions of the CNS (Park et al., 2001; Makar et al., 2002). Bone marrow cells
have been used as a delivery system to express transgenes in the CNS such as
GDNF and INF-β (Makar et al., 2004).
These studies implicating the homing of monocytes to regions of CNS
damage have led to the idea that it may be possible to use genetically modified
monocytes to carry exogenous genes of interest into the brain or other organs for
the purposes of gene therapy (Kokovay and Cunningham, 2005). Bone marrowderived monocytes could serve as an alternative to stem cells for cell and gene
therapy, because they are a safe, readily available and ethically acceptable
source (Vallieres and Sawchenko, 2003).
As an approach to increase expression of NEP in a transgenic mouse
model of AD, we developed an ex vivo gene therapy method utilizing bone
marrow monocytes from GFP mice. These monocytes were transfected with a
NEP construct designed to express either a secreted form of NEP or a form
which lacks any enzyme activity. Monocytes were located around the amyloid
plaques and we found significant reductions in both Aβ and Congo red staining in
the NEP-S injected mice only. Combining monocyte gene delivery together with
an amyloid degrading enzyme such as neprilysin offers a powerful novel
therapeutic tool for the treatment of Alzheimer’s disease.
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MATERIALS AND METHODS
Neprilysin Constructs
Endogenous neprilysin is a membrane- bound ectoprotease. Because Aβ
accumulates extracellularly in AD, we hypothesized that an extracellular
localization of protease would be most effective in degrading Aβ. Consequently,
the membrane binding domain was deleted, and a sequence triggering secretion
was added to the construct. As a control, a construct containing neprilysin with a
single-point mutation at the catalytic site precluding proteolysis was also
generated. An HA tag was appended to each construct.

Bone Marrow Collection
Transgenic GFP mice obtained from Jackson Laboratories (C57BL/6-Tg(UBCGFP)30Scha/J [Stock #004353]) were overdosed with pentobarbital. The femurs
and tibias were removed aseptically on a cold plate, and bone marrow was
flushed from the bone using a 25G 5/8 gauge needle attached to a syringe.
Single cell suspensions were prepared by repetitive pipetting and the cell
suspension was then passed through a 70 µm nylon mesh to remove particulate
matter. Cells were then collected by centrifugation for 5 minutes at 300xg (4°C).
Then cells were then incubated with RBC lysis buffer (Miltenyi Biotech, CA) for 5
minutes at room temperature. Equal volumes of PBS were added and the cells
were collected by centrifugation. Cell numbers were counted and estimated using
a hemocytometer after resuspending in RPMI 1640 medium with L-glutamine
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(Mediatech Inc., VA) supplemented with 10% heat inactivated fetal bovine serum
(FBS), streptomycin (100 µg/ml), and gentamicin (100 µg/ml).

Magnetic Cell Separation of CD11b+ Cells
After the removal of bone marrow from mice, CD11b+ cells were separated using
Miltenyi Biotec’s LS columns and MidiMacs magnet following the manufacturer’s
instructions. In summary, 107 freshly harvested bone marrow cells were
resuspended in 90 µl of medium (PBS + 0.5% BSA), mixed with 10 µl of CD11b
antibody conjugated to magnetic microbeads (Miltenyi Biotec, Auburn, CA), and
incubated for 15 minutes at 4°C. These beads can isolate cells while binding
only a fraction of the antigenic sites. The cell suspension was then applied to the
column in a magnetic field and washed with 3 mL of buffer three times. The
column was then separated from the magnet, and CD11b+ cells were eluted in
500 µl of medium and stored at 4°C. Five X 106 freshly isolated CD11b+ (GFP)
cells were then resuspended in 200 µl of RPMI 1640 medium and subjected to
transfection.

Monocyte Transfections
Monocytes were transfected using the Amaxa Mouse Macrophage Nucleofector
Kit. In brief, cells were centrifuged for ten minutes at 1000g, resuspended in 100
µl of Nucleofector Media containing 10 µg plasmid, and transferred to a cuvette.
Program Y-001 was used. After transfection, cells were transferred to a cell
culture dish and incubated at 37°for 1 hour before use.
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Transgenic mice
We used APP Tg2576 derived mice that were bred at the University of South
Florida as previously described (Holcomb et al., 1998) (Gordon et al 2002).
Tg2576 mice 16 months of age at the start of the experiment were assigned to
one of two groups. The first group received the Nep-S transfected monocytes via
intracranial injections and the second group received the Nep-M transfected
monocyte injections.

Stereotaxic Intracranial Injections
Surgery was performed on animals using a stereotaxic apparatus, injections
using the convection enhanced delivery method (CED) were of approximately
200,000 monocytes in 2μl PBS were dispensed into hippocampus and frontal
cortex at a flow rate of 2.5ul/min over a period of 0.8 min. using a blunt ended 27
gauge needle attached to a 10 μl syringe (Hamilton Co., Reno, NV). The 27
gauge needle was attached to polyethylene silicone, with an outer diameter of
165.0μm and an inner diameter of 102.0 μm, (Polymicro Technologies LLC,
Phoenix, AZ) tubing inserted into the opening of the needle and cemented in
place with super glue. The silicone tubing was then cut allowing approximately
1mm of tubing to extend from the end of the needle.

Tissue Collection and Histochemical Procedures
Mice were overdosed with pentobarbital (100mg/kg). The aorta was
clamped and the heart was perfused with saline. The brain was removed,
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bisected sagittally and the left half was immersed in freshly prepared 4%
paraformaldehyde in 100 mM PO4 buffer (pH 7.4). The brains were postfixed in
paraformaldehyde for 24 hours. The tissue was cryoprotected in a series of
sucrose solutions, frozen, sectioned in the horizontal plane at 25 µm using a
sliding microtome and stored at 4°C in Dulbecco’s phosphate buffered saline for
immunocytochemistry and histology.
Immunohistochemistry was performed on free floating sections as
described in detail previously (Gordon et al, 1997). Antibodies used for
histochemistry: Aβ (1:10,000 rabbit polyclonal prepared by Paul Gottchall); Iba1(1:3000, Wako, Richmond, VA) and GFAP (1:3000, Dako, Carpinteria, CA).
Congo Red Histology: Hydrated sections were incubated in alkaline
alcoholic saturated NaCl (2.5mM NaOH in 80% alcohol) for 20 minutes and then
incubated in 0.2% Congo red in alkaline alcoholic saturated NaCl solution for 30
minutes. Sections were rinsed through three changes of 100% ethanol, cleared
in xylene, then coverslipped with DPX.

Immunoblotting
Brain homogenates were loaded on SDS polyacrylamide gel electrophoresis and
transferred to a nitrocellulose membrane for Western blot analyses. The blots
were washed three times using Tris-buffered saline with Tween- 20 (TBST),
incubated in milk solution (TBST with 3% non fat dry milk) for 1 hour, and
washed three times with TBST. The blots were incubated in the primary antibody
(rat anti-HA; Roche, Indianapolis, IN) in milk solution (dilution 1:1000) overnight,
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washed 3 times with TBST, incubated with streptavadin horseradish peroxidase
(1:1000, Burlingame, CA) in milk solution (dilution 1:1000) for two hours, and
washed three times with TBST. The blots were enhanced with LumiGOLD ECL
Western Blot Detection Kit (SignaGen Labs; Gaithersburg, MD) and visualized on
film.

Image Analysis
GFP fluorescence, immunohistochemistry and Congo red staining were
quantified with Image Pro Plus (Media Cybernetics) image software. To quantify
the staining of the sections, we randomly sampled every 8th section from the
mouse brain. All values from each brain region obtained from a single mouse
were then averaged together to represent a single value for that animal.
Statistical analysis was performed using ANOVA followed by Fischer’s LSD post
hoc means comparison test (Statview software from SAS).

RESULTS
NEP Constructs and Expression in Vivo:
Overexpression of NEP in AD related animal models has shown a
decrease in levels of Aβ1-42, confirming the importance of this enzyme in
regulating Aβ turnover in vivo (Leissring, Farris et al. 2003; Leissring, Lu et al.
2003). In order to study the ability of NEP to degrade extracellular Aβ, we
designed a secretory form of the NEP plasmid by deleting the membrane binding
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domain and inserting a signal peptide triggering secretion (Figure 1A). The NepM-HA construct is the mutant form of the plasmid lacking any enzyme activity
and serves as control for the presence of an exogenous protein. The constructs
also contain a hemaglutinin (HA) tag to allow us to distinguish the delivered NEP
gene products from endogenous NEP found in the brain.
To verify expression of the plasmids, HEK cells were transfected with
each of the NEP constructs as well as with empty vector. Cell lysates were
collected 24 hours after transfection, and analyzed by western blotting. Both
plasmids directed strong expression.

Due to the deletion of the membrane

binding domain, the NEP-S-HA construct runs slightly lower than the NEP-M-HA
(Figure 1B).
A major challenge in working with monocytes is a difficulty in efficiently
transfecting them. Transfection efficiencies less than 10% have been
accomplished using traditional transfection techniques, including electroporation,
liposomal transfection reagents and DEAE-dextran (Mayne, Borowicz et al.
2003).

However, we have developed an effective technique that is able to

transfect approximately 50% of the monocytes using a Mouse Macrophage
Nucleofector II kit from Amaxa (Figure 2A). Staining the monocytes for HA
expression, we show that only the transfected cells are positive for HA when
compared to control transfected cells (Figure 2B).

NEP-S-HA Transfected Monocytes Reduce Aβ and Congo Red After Direct
Injection:

18 month old Tg2576 APP mice were used in these studies. To
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each of these mice, 200,000 bone marrow derived monocytes expressing NEPS-HA or NEP-M-HA were stereotaxically injected unilaterally into the right cortex
and the right hippocampus. The left side served as an uninjected control. Cells
were injected with a convection enhanced delivery method to increase the area
of distribution of the cells within the brain (Raghaven et al., 2006). The brains of
the mice were harvested 7 days after the injection and stained. To determine the
extent of Aβ clearance, horizontal brain sections were stained with an Aβ
antibody.

Representative sections are presented in Figure 3A. The amount of

staining did not appear to be altered after treatment with the monocytes
transfected with the control NEP-M-HA (left panels) in the cerebral cortex or
hippocampus. However, a reduction of Aβ in the NEP-S-HA treated mice was
observed in the cortex and the hippocampus (Figure 3A).

Percent area

quantification of Aβ immunostaining was measured using an automated image
analysis program, and is shown in Figure 3B. Significant reductions in Aβ
immunostaining were observed in the cortex (57% reduction, p < 0.01) and
hippocampus (53% reduction, p < 0.01) from mice injected with the NEP-S
construct.
To also evaluate the effectiveness of the two constructs to clear compact
plaques, brain sections were stained with Congo red. Representative
micrographs show a qualitative reduction of Congo Red stained plaques in the
NEP-S mice in the cortex and the hippocampus compared to the NEP-M injected
group. (Figure 4A). Comparing the ratios of the NEP-S and NEP-M groups show
significant reductions at the injection site in the ipsilateral cortex ( 84% reduction,
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p < 0.01) and hippocampus (69% reduction, p < 0.01) from mice injected with the
NEP-S construct (Figure 4B).

NEP Injections Do Not Cause Microgliosis or Astrogliosis.
Microglial and astrocyte activation are often a sensor for brain
inflammation or injury. Transgenic mouse models of AD have demonstrated
microglial accumulation around Aβ plaques. To determine if the injection method
increased presence of glia, we examined two common markers: IBA-1 for
microglia and GFAP for astrocytes. While there were occasional detectable
increases of staining around the needle track, we found no up-regulation of
GFAP (Figure 5) or IBA-1 (Figure 6) in the cortex or the hippocampus comparing
the injected, ipsilateral side to the uninjected side in either the Nep-S nor the
Nep-M groups. Thus, the introduction of monocytes transfected with neprilysin
did not promote brain microgliosis or astrocytosis.

DISCUSSION
Progressive accumulation of Aβ in senile plaques is regarded as a major
culprit in the onset of AD. Thus, reducing levels of cerebral Aβ represents a
logical therapeutic approach towards the disease. While most studies have
focused on the mechanisms involved in amyloid accumulation, a more important
therapeutic intervention might involve manipulating the processes involved in
amyloid degradation. NEP levels in the cortex and the hippocampus are
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significantly lower in AD brains compared to normal control brains (Iwata et al.,
2002; Caccamo et al., 2005; Yasojima et al., 2001). This is consistent with the
idea that a deficiency in NEP contributes to the accumulation of amyloid plaques.
The present study established a procedure for the isolation and transfection of
primary mouse monocytes. We also used two forms of NEP which allowed us to
clarify the role of this protease in Aβ degradation in APP transgenic mice.
Gene

therapy

holds

immense

promise

for

the

amelioration

of

neurodegenerative diseases. AD is an excellent disease to evaluate this type of
cell therapy. Amyloid exists largely outside the cells, making it accessible to
externally oriented or secreted proteins. Moreover, the disease is spread over
large portions of the cerebral cortex and the hippocampus making it difficult to
reach with viral vector injections. The blood brain barrier restricts the transport of
chemicals and large molecules into the brain and has served as a considerable
challenge for the development of gene therapies. As a result, current gene
therapies utilize direct intercranial injection of viral vectors or cells that are
transfected with a gene of interest (Marr et al., 2003, Iwata et al., 2004, Hemming
et al., 2007).
Many

cell

transplantation

studies

have

been

attempted

in

neurodegenerative diseases. In Parkinson disease as well as in Alzheimer’s
disease growth factors have been transfected in cells and transplanted into the
brain (Freed et al, 1991, Lindvall et al, 1991, Tuszynski et al., 2005). However
these studies have not shown great promise as a result of survival of grafted
cells as well as ethical issues involved with using embryonic cells. While stem
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cells may eventually serve an important cell vector for gene therapy, a better
understanding of how these cells differentiate and proliferate is crucial before
they can be used in gene therapy studies. As a result, a search for a primary cell
has been needed. Our present study shows that monocytes can be easily
isolated and injected in the brain and that after injection these cells survive up to
7 days. This is in agreement with Kennedy and Abkowitz (1998) as well as
Zassler and Humpel 2006 who demonstrated a similar survival time of
monocytes post injection in the brains of rodents.
Studies showing that hematopoietic cells can enter the brain in AD and
differentiate into microglia/macrophages at sites of Aβ plaques have resulted in
multiple research groups alluding to the use of monocytes as vehicles by which
genes can be delivered to the brain (Priller 2001, Biffi 2004, Asheuer 2004,
Zassler and Humpel 2006). These cells are readily available in the bone marrow
or blood, and as we have previously shown, have the ability to migrate through
the BBB to the brain and associate around Aβ plaques. A monocyte gene
therapy approach has a number of positive benefits compared to other cells
types such as stem cells or progenitor cells. Monocytes have short lifespans in
vivo allowing adverse reactions to resolve over time. The transfection of
autologous monocytes should have a low probability of eliciting an immune
reaction against the gene therapy vector. And most importantly, this approach
would have the benefits of access to the entire brain, and concentration of the
therapeutic gene at the sites of brain injury.
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While many studies have implicated the use of monocytes as an ideal cell
vector for gene therapy in AD, it is crucial to optimize in vitro transfection
methods to genetically modify primary monocytes ex vivo. There have only been
a small number of studies focused on the separation and cultivation of
monocytes (Grace et al., 1988, Agger et al., 2000, Zeng et al 2006). Typically
transfection efficiencies of less than 10% have been achieved using standard
transfection protocols (Burke et al 2002, Harwood et al 2002). This low level of
transfection is not functional for an ideal scientific study. However in our study,
we have found a method to harvest, isolate and transfect monocytes and reinject them back into an animal within hours. To study the ability of monocytes to
serve as gene therapy vectors it was essential to separate a homogeneous
monocytic cell population from the total bone marrow cell population. While
monocytes are available in the circulation, the percentage of monocyte cells is
much greater in bone marrow than in the blood. It has also been shown that
monocytes isolated from bone marrow were more receptive to viral vector
mediated transduction than monocytes from mouse blood (Zeng et al, 2006).
The lack of a specific marker on monocytes has also made these cells
difficult to study. The literature has previously presented methods to obtain pure
monocyte populations from bone marrow, by allowing these cells to culture and
adhere for 7 days (Chu et al., 2005). However in recent years, studies have
suggested that with increasing time in culture the phenotypes of monocytes
isolated from mouse, rat, or human brain change considerably from the
phenotypes observed immediately ex vivo (Ford et al., 1995; Carson et al.,1998;
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Carson et al., 1999). Consequently, we elected to use the cell surface expression
of CD11b as a selection marker for monocytes to separate a purified population
of monocytic cells from total bone marrow in mice through the use of Miltenyi
Biotec’s LS columns ™ and MidiMacs ™. Using a magnetic cell separation kit we
can enrich our monocyte population and increase the number of monocytes
injected into the brain instead of using total bone marrow. We have also used a
Mouse Macrophage Nucleofector II kit from Amaxa which allows us to transfect
about 50% of monocytes within a matter of seconds. The NEP plasmids are also
tagged with HA and post transfection we have shown that only the transfected
cells are positive for HA when compared to control transfected cells.
We have shown that the secreted form of NEP was extremely effective at
clearing both diffuse and compact Aβ from the brain compared to the NEP-M
plasmid which lacked any enzyme activity. There was a significant reduction of
both Aβ and Congo Red near the injection site in the NEP-S mice in the cortex
and the hippocampus compared to the NEP-M injected group. Thus removal of
Aβ appears to occur through the diffusion of the protease throughout the injection
site. While upregulating NEP may affect other substrates since it is involved in
the degradation of other species besides Aβ, we did not examine any up
regulation of microglia or astrocytes as a result of the secreted protein.
NEP expression is most likely regulated by many factors that have been
implicated in AD with the most notable being aging. While there is no clear
understanding what mechanisms cause the age decline in NEP brain levels, it
has been shown that there is a definitive decrease in NEP mRNA in the brains
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and CSF of AD patients (Wang et al., 2005, Russo et al, 2005). While NEP is a
critical protease involved in Aβ clearance, there are several other Aβ degrading
enzymes that are likely to play a pivotal role in the removal of Aβ in the brain. IDE
and ECE have also been shown to degrade Aβ in vivo, suggesting that each
protease may target a different cell or region in the brain and work together
through a synergistic effect by targeting different Aβ fragments (Farris et al.,
2003, Eckman et al., 2003, Eckman and Eckman, 2005). It is therefore possible
that in addition to NEP, other peptidases may contribute to the degradation of Aβ
(Chesneau et al, 2000). Regardless, the data presented in this study support the
hypothesis that NEP plays a significant role in Aβ clearance.
In conclusion, our study establishes a systematic procedure for the
isolation and transfection of primary mouse monocytes. We also demonstrate
proof of principle that NEP secreting monocytes are useful for transplantation into
the brain and delivery of recombinant NEP in degrading Aβ plaques. Such
monocytes may be useful to deliver therapeutic NEP into the brain in
neurodegenerative diseases such as AD. Thus we think that transmigration of
NEP-secreting monocytes through the BBB into the brain could offer a novel
alternative to transplantation studies.
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Figure 1: CHARACTERIZATION OF NEP CONSTRUCTS:
(A)

Schematic representation of the constructs expressing NEP-S (NEPs) and

NEP-M (NEPm). The plasmids express the NEP gene under the control of the
chicken β-actin promoter. Note the HA tag present on each construct. The NEPS construct also has a signaling peptide inserted to direct secretion of the
enzyme. The NEP-M construct is identical to the NEP-N construct with the
exception of a single point mutation at the amino acid point E585V.
(B)

HEK cells electroporated with the plasmids discussed in (A). Lysates were

collected and probed for HA on an immunoblot. Due to the deletion of the
membrane binding domain, NEP-S runs lower on the gel as seen on the blot.

(A)
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(B)

115 kDa →
82 kDa →
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Figure 2: STAINING AND TRANSFECTION EFFICIENCIES OF NEP
CONSTRUCTS
(A)

Bivariate plots of FACS analysis to analyze cell viability with propidium

iodide (PI) and transfection efficiency with GFP fluorescence after electroporation
of a GFP-expressing construct. A minimum of 10,000 viable cells were acquired
and GFP expression was quantified by gating out the (PI+) dead cells. Data are
presented as density plots. The second plot shows that 54% of the live cells
expressed the transfected GFP plasmid.
(B)

Cells transfected with GFP are shown in the top row of images (Panel a),

while cells transfected with a control plasmid do not express GFP as seen in
(Panel b). Cells transfected with NEP construct are positively stained for HA as
seen in the bottom row of images (Panel c).
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GFP Brightfield
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Non transfected monocytes

Non transfected Brightfield
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HATransfected monocytes

Non transfected monocytes
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Figure 3: TOTAL Aβ IS SIGNIFICANTLY REDUCED IN THE FRONTAL
CORTEX AND HIPPOCAMPUS FOLLOWING NEP-S INJECTION. APP
transgenic mice were injected with monocytes expressing either NEP-S-HA or
NEP-M-HA into the right cortex and hippocampus. Brains were harvested 7 days
post injection. Images showing staining of plaque burden at the sites of injection,
with the uninjected, contralateral left cortex (top row) and hippocampus (lower
row) serving as control. (Panel A). The graph shows the quantification of percent
area of total Aß staining in the frontal cortex and hippocampus after a single
injection of either NEP-S or NEP-M construct (B). * indicates P<0.05 and **
indicates P<0.01; when compared to mice treated with NEP-M construct.
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(B)
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Figure 4: COMPACT CONGOPHILIC AMYLOID DEPOSITS ARE REDUCED
BY NEP-S CONSTRUCT.
18 month old APP transgenic mice were injected with monocytes expressing
either NEP-S-HA or NEP-M-HA. Cells were stereotaxically injected into the right
cortex and hippocampus, with the uninjected left cortex and hippocampus
serving as a control. Brains were harvested 7 days post injection. Representative
micrographs show a qualitative reduction in staining in the NEP-S-HA treated
group (A). The graph shows the quantification of percent area of total Aß staining
in the frontal cortex and hippocampus after a single CED injection of either NEPS or NEP-M construct (B). * indicates P<0.05 and ** indicates P<0.01; when
compared to mice treated with NEP-M construct.
(A)
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(B)
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Figure 5: THERE IS NO CHANGE IN GFAP STAINING IN THE FRONTAL
CORTEX AND HIPPOCAMPUS FOLLOWING NEP-S INJECTION
Brain sections showing GFAP staining from both the contralateral and ipsilateral
sides of the cortex and hippocampus in both the NEP-M and NEP-S mice (A).
The graph shows the quantification of percent area of total GFAP staining in the
frontal cortex and hippocampus after a single injection of either NEP-S or NEP-M
construct (B).

(A)
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(B)
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Figure 6: THERE IS NO CHANGE IN MICROGLIAL STAINING IN THE
FRONTAL CORTEX AND HIPPOCAMPUS FOLLOWING NEP-S INJECTION
Brain sections showing IBA-1 staining from both the contralateral and ipsilateral
sides of the cortex and hippocampus in both the NEP-M and NEP-S mice (A).
The graph shows the quantification of percent area of total IBA-1 staining in the
frontal cortex and hippocampus after a single injection of either NEP-S or NEP-M
construct (B).

(A)
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ABSTRACT
The accumulation of amyloid-β protein (Aβ) in Alzheimer’s disease (AD) is
a well known pathological event. Decreasing the production or increasing the
degradation of Aβ is therefore thought to serve as a potential therapeutic
intervention in AD. Recent in vitro and in vivo studies have suggested that certain
proteases may be involved in the catabolism of Aβ and defects in the
degradation of Aβ could contribute to AD disease progression. Additionally,
studies implicating the homing of monocytes to regions of CNS damage have led
to the idea that it may be possible to use genetically modified monocytes to carry
exogenous genes of interest into the brain or other organs for the purposes of
gene therapy.
As an approach to increase expression of NEP in a transgenic mouse
model of AD, we developed an ex vivo gene therapy method utilizing bone
marrow monocytes from GFP mice. These monocytes were transfected with a
NEP construct designed to express either a secreted form of NEP or a form
which lacks any enzyme activity.

Monocytes were administered through a

microvascular port twice a week for two months and we observed recruitment of
bone marrow-derived monocytes into the CNS. In addition, we found significant
reductions in both Aβ and Congo red staining in the NEP-S injected mice only.
These studies show that putting monocytes together with an amyloid degrading
enzyme such as neprilysin offers a powerful novel therapeutic tool for the
treatment of AD.
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INTRODUCTION
The senile plaque is a pathological hallmark of Alzheimer’s Disease (AD)
and is composed of Aβ, activated microglia, astrocytes, and degenerating
neurons (Dickson et al., 1988; Selkoe, 2000; Mott and Hulette, 2005). Microglia
play a key role as the resident mononuclear phagocyte population in the CNS
(Perry and Gordon, 1988). These cells share many phenotypical and functional
characteristics with other tissue macrophages and with peripheral blood
monocytes, suggesting that microglia participate in many immune reactions of
the brain.
Microglia originate from the bone marrow and emigrate to the blood as
monocytes (Review: Gordon and Taylor, 2005). Despite tremendous efforts in
the past, monocyte derived and resident CNS microglia remain almost
indistinguishable on the basis of known immunophenotypic markers (Simard et
al., 2006). However, using chimeric mice, in which bone marrow cells were
marked with GFP, MHCII, Y chromosome, congenic CD45,1/CD45.2 molecules,
and others, bone marrow derived cells were shown to enter the brain and
differentiate into microglia (Tacke et al., 2006; Imari et al., 2002; Rivier et al.,
2004; Hickey et al., 1992; Priller et al., 2001 ). Subsequent studies in mice have
even shown an increase in microglial engraftment in several disease models
such as experimental autoimmune encephalomyelitis (EAE) (Heppner et al.,
2005), Parkinson’s Disease (PD) (Kokovay and Cunningham, 2005) and AD
(Malm et al., 2005; Stalder et al., 2005). These observations have provided the
basis for work aimed at using autologous bone marrow to deliver therapeutic
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genes to damaged regions of the CNS (Park et al., 2001; Makar et al., 2002).
Bone marrow cells have been used as a delivery system to express transgenes
in the CNS such as GDNF and IFN-β (Makar et al., 2004).
Recent in vitro and in vivo studies have suggested that certain proteases
may be involved in the catabolism of Aβ and defects in the degradation of Aβ
might play a role in AD disease progression. Neprilysin (NEP) is a membrane
bound zinc metallopeptidase that has implicated in degradation of both
extracellular and intracellular Aβ (Iwata et al., 2001). The location of NEP at the
presynapses and on axons indicates that this protease may play a key role in Aβ
catabolism at and around neuronal synapses. Consequently a reduction of NEP
activity may cause a local increase in the concentration of Aβ at these regions.
An aging dependent decline in NEP level occurs naturally in regions which are
generally affected in AD (Fukami et al., 2002; Maruyama et al., 2005; Wang et
al., 2005). Thus, a proposed potential therapeutic strategy to prevent the
accumulation of Aβ would be to re-establish NEP activity in the brain.
The blood brain barrier (BBB) strictly limits the transport of soluble
materials, pathogens and large moleculess into the brain and thereby helps to
maintain a protected environment within the CNS (Krol and Neuwelt, 198; Zhang
and Pardridge, 2001). The BBB is vital for normal brain function but represents a
considerable complication in the development of gene therapeutic interventions
for neurodegenerative diseases. Current CNS gene therapy studies therefore
rely on the direct injection of vectors or cells that contain a therapeutic gene of
interest (Bloch et al., 2004; Crystal et al., 2004; Janson et al., 2002). This
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generates limitations which include the risk for CNS damage as a consequence
of drilling holes into the skull and introducing catheters to deliver genes.
Therefore, noninvasive and safer gene delivery methods are needed.
As an approach to increase expression of NEP in a transgenic mouse
model of AD, we developed an ex vivo gene therapy method utilizing bone
marrow monocytes from GFP mice. These monocytes were transfected with a
NEP construct designed to express either a secreted form of NEP or a form
which lacks any enzyme activity.

Monocytes were administered through a

microvascular port twice a week for two months and we observed recruitment of
bone marrow-derived monocytes into the CNS. In addition, we found significant
reductions in both Aβ and Congo red staining in the NEP-S injected mice only.
The GFP-positive monocytes visualized in the brain associated with amyloid
plaques and retained the hematopoietic marker CD11b. Cells of amoeboid shape
also expressed a macrophage marker, CD68, indicating a dual role for these
cells. These studies show that putting monocytes together with an amyloid
degrading enzyme such as neprilysin offers a powerful novel therapeutic tool for
the treatment of AD.
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METHODS
Neprilysin Constructs
Endogenous neprilysin is a membrane- bound ectoprotease. Because Aβ
accumulates extracellularly in AD, we hypothesized that an extracellular
localization of protease would be most effective in degrading Aβ. Consequently,
the membrane binding domain was deleted, and a sequence triggering secretion
was added to the construct. As a control, a construct containing neprilysin with a
single-point mutation at the catalytic site precluding proteolysis was also
generated. An HA tag was appended to each construct.

Bone Marrow Collection
Transgenic GFP mice obtained from Jackson Laboratories (C57BL/6-Tg(UBCGFP)30Scha/J [Stock #004353]) were overdosed with pentobarbital. The femurs
and tibias were removed aseptically on a cold plate, and bone marrow was
flushed from the bone using a 25G 5/8 gauge needle attached to a syringe.
Single cell suspensions were prepared by repetitive pipetting and the cell
suspension was then passed through a 70 µm nylon mesh to remove particulate
matter. Cells were then collected by centrifugation for 5 minutes at 300xg (4°C).
Then cells were then incubated with RBC lysis buffer (Miltenyi Biotech, CA) for 5
minutes at room temperature. Equal volumes of PBS were added and the cells
were collected by centrifugation. Cell numbers were counted and estimated using
a hemocytometer after resuspending in RPMI 1640 medium with L-glutamine
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(Mediatech Inc., VA) supplemented with 10% heat inactivated fetal bovine serum
(FBS), streptomycin (100 µg/ml), and gentamicin (100 µg/ml).

Magnetic Cell Separation of CD11b+ Cells
After the removal of bone marrow from mice, CD11b+ cells were separated using
Miltenyi Biotec’s LS columns and MidiMacs magnet following the manufacturer’s
instructions. In summary, 107 freshly harvested bone marrow cells were
resuspended in 90 µl of medium (PBS + 0.5% BSA), mixed with 10 µl of CD11b
antibody conjugated to magnetic microbeads (Miltenyi Biotec, Auburn, CA), and
incubated for 15 minutes at 4°C. These beads can isolate cells while binding
only a fraction of the antigenic sites. The cell suspension was then applied to the
column in a magnetic field and washed 3 mL of buffer 3 times. The column was
then separated from the magnet, and CD11b+ cells were eluted in 500 µl of
medium and stored at 4°C. Five X 106 freshly isolated CD11b+ (GFP) cells were
then resuspended in 200 µl of RPMI 1640 medium and subjected to transfection.

Monocyte Transfections
Monocytes were transfected using the Amaxa Mouse Macrophage Nucleofector
Kit. In brief, cells were centrifuged for ten minutes at 1000g, resuspended in 100
µl of Nucleofector Media containing 10 µg plasmid, and transferred to a cuvette
for nucleofection, Program Y-001. After transfection, cells were transferred to a
cell culture dish and incubated at 37° for 1 hour before use.
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Implantation of Microvascular Port
The microvascular ports (Kent Scientific) are 9x9x3 mm polyurethane ports that
were placed subcutaneously in the nape of the neck of a mouse and are
connected via catheter to the right jugular vein. A skin incision was made over
the area of the right jugular, a sterile trocar tunneled to the soft tissue between
the scapula and an incision placed at the tip of the trocar. The vessel was
dissected free from surrounding tissue. A proximal and distal ligature were
placed around the vessel. The distal ligature was ligated, and a venotomy was
performed and the catheter advanced into the jugular vein 5 mm. The proximal
suture was placed around the catheter and secured. A subcutaneous pocket
was made between the scapulae, and the port was placed into the pocket. Both
incisions were closed with suture. The catheter was flushed with 100unit per ml
heparin in saline solution, approximately three times the dead space of catheter
(30 µl). On the day of injection, mice were anesthetized with isoflurane, the
catheter was cleared by inserting a 27 g needle through the skin into the port and
injecting 30 µl of 100U/ml heparin in saline, followed by 100 µl of monocyte cell
suspension, followed by another 30 µl of the heparin solution.

Transgenic mice
We used APP Tg2576 derived mice that were bred at the University of South
Florida as previously described (Holcomb et al., 1998) (Gordon et al 2002).
Tg2576 mice 9 months of age, at the start of the experiment were assigned to
one of three groups. The first group received the Nep-S transfected monocytes
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injections via the microvascular port and the second group received the Nep-M
transfected monocyte injections. These mice were injected twice a week for two
months. The third group did not receive any injections of monocytes and served
as a baseline control.

Tissue Collection and Histochemical Procedures
Mice were overdosed with pentobarbital (100mg/kg). The aorta was
clamped and the heart was perfused with saline. The brain was removed,
bisected sagittally and the left half was immersed in freshly prepared 4%
paraformaldehyde in 100 mM PO4 buffer (pH 7.4). The brains were postfixed in
paraformaldehyde for 24 hours. The tissue was cryoprotected in a series of
sucrose solutions, frozen, sectioned in the horizontal plane at 25 µm using a
sliding microtome and stored at 4°C in Dulbecco’s phosphate buffered saline for
immunocytochemistry and histology.
Immunohistochemistry was performed on free floating sections as
described in detail previously (Gordon et al, 1997). Antibodies used for
immunohistochemistry: CD11b (rat monoclonal anti CD11b, Serotec, Raleigh,
NC); GFP (rabbit monoclonal anti-GFP; Chemicon, Temecula, CA), 6E10
(Covance, Emeryville, CA); CD68 (Serotec, Raleigh, NC). Single and multiple
immunofluorescent labeling: after incubation with the primary antibody, the free
floating sections were then incubated for 2 hours with the appropriate fluorophore
coupled secondary antibodies [AlexaFluor 594 (1:1500), AlexaFluor 488
(1:1500), AlexaFluor 350 (1:1500) (Molecular Probes, Eugene, OR]. Sections
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were rinsed in Delbecco’s PBS and coverslipped with VECTASHIELD Mounting
Medium with DAPI.
Congo Red Histology: Hydrated sections were incubated in alkaline
alcoholic saturated NaCl (2.5mM NaOH in 80% alcohol) for 20 minutes and then
incubated in 0.2% Congo red in alkaline alcoholic saturated NaCl solution for 30
minutes. Sections were rinsed through three changes of 100% ethanol, cleared
in xylene, then coverslipped with DPX.

Immunoblotting
Brain homogenates were prepared according to (Cardona et al., 2006) and were
loaded on SDS polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane for Western blot analyses. The blots were washed three
times using Tris-buffered saline with Tween- 20 (TBST), incubated in milk
solution (TBST with 3% non fat dry milk) for 1 hour, and washed three times with
TBST. The blots were incubated in the primary antibody (rat anti-HA; Roche,
Indianapolis, IN) in milk solution (dilution 1:1000) overnight, washed 3 times with
TBST, incubated with streptavadin horseradish peroxidase (1:1000, Burlingame,
CA) in milk solution (dilution 1:1000) for two hours, and washed three times with
TBST. The blots were enhanced with LumiGOLD ECL Western Blot Detection Kit
(SignaGen Labs; Gaithersburg, MD) and visualized on film.
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Image Analysis
GFP fluorescence, immunohistochemistry and Congo red staining were
quantified with Image Pro Plus (Media Cybernetics) image software. To quantify
the staining of the sections, we randomly sampled every 8th section from the
mouse brain. All values from each brain region obtained from a single mouse
were then averaged together to represent a single value for that animal.
Statistical analysis was performed using ANOVA followed by Fischer’s LSD post
hoc means comparison test (Statview software from SAS).

RESULTS
NEP-S-HA Transfected Monocytes Reduce Aβ and Congo Red After Direct
Injection: Total Aβ is comprised of both compact and diffuse amyloid deposits
that can be quantified using immunohistochemical methods. Tg2576 mice 9
months of age, at the start of the experiment were assigned to one of three
groups. The first group received the NEP-S transfected monocyte injections via
the microvascular port and the second group received the NEP-M transfected
monocyte injections. The third group did not receive any injections of monocytes
and served as a baseline control. Representative immunostaining micrographs in
the frontal cortex and hippocampal regions from each group are shown in Figure
1A. A qualitative reduction in Aβ can be seen in both the cortex and the
hippocampus in the NEP-S treated group with levels of Aβ comparable to the 9
month old untreated mice. Quantification of the percent area of positive staining
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showed a significant reduction in Aβ staining in the NEP-S treated mice in both
the cortex and hippocampus (Figure 1B).
The removal of compact plaques through NEP mediated degradation has
remained speculative. Congo red binds to the beta-pleated sheet conformation of
fibrillar Aβ and allows us to detect compact amyloid plaques. Following peripheral
injections of neprilysin transfected monocytes, we observed a significant
reduction of Congo red staining in the NEP-S treated mice compared to the NEPM and the untreated control mice (Figure 2A). Quantification of the total area
occupied by Congo red stain revealed a significant reduction in the frontal cortex
and hippocampus with the NEP-S treated mice (Figure 2B). These levels again
were comparable to 9 month old treated mice, suggesting that the treatment of
NEP-S halted the progression of amyloid deposition of the mice.

HA is detected in brain tissue but not in plasma.
To determine the effects that the NEP-S might have on the periphery and the
CNS, we probed the plasma and brains of the mice for HA 24 hours following the
last injection. Western blot analysis (Figure 3) using an antibody against HA
detected the presence of the HA tag in the NEP-S and NEP-M brain and not the
uninjected control mice proving we could correctly identify the presence of HA.
We did not detect the presence of HA in the plasma of any of the mice implying
that NEP expression was only affecting the CNS.
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Transfected GFP+ monocytes migrated to the brain vicinity of amyloid
plaques. Imaging of GFP-positive cells was done using confocal microscopy.
Brain sections were stained with Aβ (blue), CD11b (red), and GFP (green) to
detect the location and phenotype of the injected monocytes (Figure 4).
Approximately 95% of GFP positive cells were positive for CD11b confirming
their hematopoietic origins. Cells were located throughout the brain and revealed
an association with amyloid plaques. These amyloid plaques were also
surrounded by resident microglia (i.e. GFP negative and CD11b positive cells).
We also know that peripheral monocytes can enter the brain and serve as CNS
macrophages. To analyze this we stained brain sections with CD68, a
macrophage marker and found that GFP-positive cells also co-localized with this
marker (Figure 5). It is interesting to note that the cells that were labeled with
CD68 remained in an amoeboid state, while those cells that had begun to display
ramifications did not posses this marker.

DISCUSSION
NEP expression in the brain has been shown to decrease during aging
and in the beginning stages of AD progression (Iwata et al., 2002; Caccamo et
al., 2005). Therefore finding a way to selectively up regulate brain NEP activity
has been proposed as a therapeutic treatment to stop the progression of AD. The
results reported here confirm that injected GFP-positive monocytes derived from
the bone marrow migrate from the periphery into the brains of APP+PS1
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transgenic mice. Furthermore, we have found that this migration is rapid, with
numerous cells present twenty four hours after transplant. These new cells were
distributed throughout the brain and appear to reside within the parenchyma,
because following perfusion with PBS these cells remained in the brain.
Double labeling analyses show that almost all GFP+ monocytes retained
the hematopoietic marker CD11b. These finding are in agreement with others
who have reported that BMDCs retain a hematopoietic phenotype in the brain
(Vallieres and Sawchenko, 2003; Wehner et al., 2003). In addition, we also
observed cells positively labeled for CD68, a marker for macrophages. While we
did not actually determine if the GFP-positive cells were phagocytosing Aβ,
increasing evidence has hypothesized that microglia may play a protective role in
AD by mediating clearance of Aβ. Indeed, when we compared the amount of
amyloid in the three treatment groups, we saw a small trend in the NEP-M
treated group that may indicate peripheral derived monocytes alone could delay
the progression of AD like pathology. However several groups have shown that
during the aging process, the expression of microglial Aβ receptors and Aβ
degrading enzymes declines, resulting in decreased Aβ uptake and degradation
and increased Aβ accumulation. Fiala et al., also found that monocytes and
macrophages from AD patients displayed ineffective phagocytosis of Aβ when
compared with monocytes and macrophages from age matched control non AD
patients. While it is not certain what mechanisms are responsible for the
decreased expression of degrading enzymes, reactive oxygen species and proinflammatory cytokines have been found to increase in transgenic mice with AD
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pathology and may play a role in this process (El Khoury et al., 2008; Hickman,
2008).
We have shown that the secreted form of NEP was extremely effective at
clearing both diffuse and compact Aβ from the brain compared to the NEP-M
plasmid which lacked any enzyme activity. There was a significant reduction of
both Aβ and Congo Red staining in the NEP-S mice in the cortex and the
hippocampus compared to the NEP-M and control group. The levels of Aβ were
comparable to that of a 9 month of APP+PS1 mouse indicating that the NEP-S
transfected monocytes halted the progression of amyloid deposition by up
regulating NEP in the brains of these animals. While increasing NEP in the brain
may affect other substances, since it is involved in the degradation of other
species besides Aβ, during the two months of injections we found no signs of
weight loss or deteriorating health.
Ex vivo gene therapy represents a novel method of treatment for a variety
of neurodegenerative diseases. However, in order to develop a successful ex
vivo gene therapy it is essential to establish an effective method for the delivery
of bone marrow derived monocytes into the CNS of APP+PS1 transgenic mice.
In current studies of bone marrow monocyte transplantation, we as well as other
groups have demonstrated the inability to deliver significant numbers of
monocytes into the brain following intraperitoneal or tail vein infusion (Malm et
al., 2005; Djukic et al., 2006; Andreesen et al., 1990). In addition, the feasibility of
long term tail vein injections is limited by the fact that scar tissue can form and
decrease the available area for an injection site. In this study, the use of the
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mouse microvascular port was a novel and critical method that aided in the
significant number of GFP positive cells seen in the brain. This route of cell
injection will be critical for all future cells therapies tested over a long term study
and provide a reliable induction of cells into the blood stream.
While many neurotrophic factors show promise in the treatment of
neurodegenerative disorders, their use has been limited due to their inability to
cross the blood brain barrier and by their limited diffusion throughout the brain
(Verall, 1994). The use of bone marrow derived monocytes to deliver therapeutic
genes directly to brain should result in a low probability of eliciting an immune
reaction as well as concentrating the therapeutic gene at the site of brain injury.
However the development of reversible or controlled expression systems will be
critical to avoid unwanted side effects that may in the long term alter the immune
system or result in the increase of secondary side effects.
NEP expression is most likely regulated by many factors that have been
implicated in AD with the most notable being aging. In support of this Fukami et
al., reported significant age related reductions in NEP expression in amyloid
vulnerable regions of transgenic mouse brains. Similar results were obtained by
Caccamo et al., who showed that the levels NEP decrease with age in the mouse
hippocampus but not in the cerebellum, which is resistant to amyloid deposition.
Recently, in addition to neprilysin, several peptidases such as endothelin
converting enzyme 1 (ECE1), endothelin converting enzyme 2 (ECE2), and
insulin degrading enzyme (IDE) have been identified as Aβ degrading enzymes
through the use of transgenic knockout mouse models (Eckman et al., 2003;
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Farris et al., 2003; Miller et al., 2003). While neprilysin has been shown to have
the greatest effect in the reduction of Aβ, each of these peptidases is likely to
play a different role in the total Aβ clearance in the brain. Their differences in
enzymatic and cellular locations are likely to play additive, or synergistic roles in
the removal of Aβ (Eckman et al., 2001; Saido and Nakahara, 2003). Developing
a cell therapy that can incorporate the degrading properties of each of these
enzymes may therefore result in an effective combination therapy that could
result in total Aβ clearance.
In conclusion, our results demonstrate that ex vivo gene delivery of an Aβ
degrading enzyme halted the progression of amyloid deposition. However, there
are still many questions that still need to be addressed to further develop new
gene/cell therapeutic treatments. Defining the impact of the donor and recipient
age as well as the signaling interaction between Aβ and peripheral monocytes
will be critical for the development of new gene delivery approaches and may
reveal new therapeutic targets. Harnessing the peripheral immune system to
pharmacologically control brain Aβ levels may serve as a powerful new tool to
improve recovery and repair brain damage for the treatment of AD.
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Figure 1: TOTAL Aβ IMMUNOHISTOCHEMISTRY IS SIGNIFICANTLY
REDUCED IN NEP-S TREATED MICE.
9 month old APP+PS1 transgenic mice were injected peripherally with
monocytes expressing either NEP-S (n=8) or NEP-M (n=9) once a week for two
months. The control mice (n=7) did not receive any injection over the two month
period. Brains were harvested 24 hours post last injection. Panel A shows 6E10
Aβ immunohistochemistry in the frontal cortex and hippocampus of mice. Panel B
shows quantification of percent area of total Aß staining in the frontal cortex and
hippocampus. Statistical analysis was performed using one-way ANOVA with
Fisher’s LSD multiple comparison test. Brackets between bars signify statistical
significance (p<0.05). Values are mean ± SEM (standard error of mean).
Magnification = 40X. Scale bar = 120 µm for all panels.
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Figure 2: CONGO RED STAINING IS SIGNIFICANTLY REDUCED IN NEP-S
TREATED MICE.
Brain sections from each group were stained with Congo Red to quantify fibrillar
plaques. Micrographs in panel A show Congo Red staining in the frontal cortex
and hippocampus of mice. Panel B shows quantification of percent area of total
Congo Red staining in the frontal cortex and hippocampus. Statistical analysis
was performed using one-way ANOVA with Fisher’s LSD multiple comparison
test. Brackets between bars signify statistical significance (p<0.05). Values are
mean ± SEM (standard error of mean). Magnification = 40X. Scale bar = 120 µm
for all panels.
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Figure 3: HA is detected in brain tissue but not in plasma.
Lysates were loaded for Western blot analysis performed using antibody to HA.
Nep-S transfected HEK cells (lane 1), brain lysates (lanes 2, 4, 6) and plasma
lysates (lanes 3,5,7). These blots are representative of larger blots showing
similar results.

113

Figure 4. GFP positive monocytes migrate to plaques in APP+PS1
transgenic animals and retain hematopoietic marker.
Imaging of GFP-positive cells was done using confocal microscopy. Brain
sections were stained with fluorescent markers to detect the location and
phenotype of the injected monocytes. Almost all GFP cells co localized with
CD11b (a-c and d-f). No GFP positive cells were detected in uninjected control
mice (g-i). Pictures were taken at 63X and scale bar = 20 µm.
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Figure 5. A subpopulation of GFP+ cells express a macrophage phenotype.
Ameboid cells expressed both GFP and CD68, while cells which displayed
ramifications expressed only GFP (a-c and d-f). No GFP positive cells were
detected in uninjected control mice (g-i). Pictures were taken at 63X and scale
bar = 20 µm.
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CONCLUSIONS
Alzheimer’s disease (AD) is a progressive age related neurodegenerative
disorder that afflicts more than 13 million people worldwide. Clinically, AD
patients exhibit an inability to assimilate new information, and as the disease
progresses both declarative and non declarative memory become even more
profoundly impaired. The pathological features of AD include senile plaques,
neurofibrillary tangles and neuron loss. According to the amyloid cascade
hypothesis, aggregation of β-amyloid in senile plaques is an early and necessary
event in AD (Hardy and Higgins, 1992; Hardy and Selkoe 2002).
There is substantial evidence in favor of the amyloid hypothesis which has
recently been the subject of a number of reviews (Sisodia, 1999; St. GeorgeHyslop, 1999). The strongest evidence in favor of it is the finding that multiple
point mutations in the amyloid precursor protein (APP), presenilin I and presenilin
II, all result in overproduction of the 42 amino acid form of Aβ. Each of these
mutations results in the familial form of the disease which neuropathologically
looks very similar to that of sporadic AD. For this reason, a number of
laboratories and pharmaceutical companies are attempting to develop treatments
that reduce the production of Aβ with the hope that this will reduce the symptoms
and clinical progression of the disease. Several potential methods have been
proposed for removal of Aβ deposits, including vaccination (Schenk et al., 1999),
gene therapy (Marr et al., 2004), and cell therapy (Bard et al., 2000; Wyss –
Coray et al., 2003).
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Traditionally thought of as an immunologically privileged organ, today the
CNS is known to have an endogenous immune system that works through the
interaction of immunocompetent cells such as astrocytes and microglia. Microglia
are found throughout the CNS; comprising between 5-15% of the cells (Federoff
et al., 1995; Kreutzberg et al., 1996; Streit et al., 1995). Their activation is an
early response to CNS injury and is a feature of several brain pathologies
including AIDS dementia, Multiple Sclerosis, Alzheimer’s and Down’s Syndrome.
Unclear in these neuropathologies are the relative contributions of resident
microglia versus infiltrating macrophages toward neurodegeneration on one hand
and toward neuroprotection on the other.
It is now generally accepted that adult mouse microglia originate from
monocytes/macrophage precursor cells migrating from the yolk sac into the
developing CNS (Pessac et al., 2001; Alliot et al., 1999). Once CNS residents,
these newly migratory cells actively proliferate during development, thereby
giving rise to the resident CNS microglial population. More recently however, it
has been shown that bone marrow derived cells can continuously enter the CNS
and become cells that phenotypically resemble resident microglia in the adult
mouse (Eglitis and Mezey, 1997; Brazelton et al., 2000; Mezey et al., 2000).
Because peripheral and resident microglia have similar phenotypic
markers it has been difficult to identify which cells play a role in AD disease
pathology. However, since we are now able to track the migration of GFP labeled
cells, it is possible to identify the location from which these cells are originating.
The migratory route monocytes take once leaving the bone marrow is currently
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unclear and previous work has suggested that hematopoietic cells may migrate
into the brain parenchyma to give rise to microglia (Massengale et al 2005, Priller
et al., 2001, Vallieres et al., 2003).
To approach the question of how long bone marrow derived monocytes
stay in the blood we used transplanted GFP labeled bone marrow monocytes to
characterize the kinetics that peripheral monocytes display once injected into the
circulation. Using flow cytometry we were able to identify the GFP monocytes in
the blood and determine their relative numbers at each of the time points (Figure
1). As we hypothesized, the injected monocytes spent very little time in the blood
stream. Given the data we were able to determine the half life of these cells to be
1.5 hours following the injection. By 24 hours we were not able to find any GFP
labeled monocytes in the blood circulation.
Although previous studies have demonstrated infiltration of peripheral
monocytes following bone marrow irradiation and GFP reconstitution, the percent
contribution of circulating monocytes to the microglial reaction in brains has not
been investigated. To examine the effects of the APP+PS1 transgene on the
recruitment on peripherally injected monocytes, we compared the migration route
to various organs in both non transgenic and 16 month old APP+PS1 mice.
Quantification of cell numbers in each organ was analyzed at 1, 3, and 7 days
post cell injection using both stereological (Paper 1: Figure 2A) and flow
cytometry analysis (Paper 1: Figure 2B). The APP+PS1 mice recruited a
significant number of GFP positive cells to the brain following a single injection
(Paper 1: Figure 3). These cells were found mainly in the cortex and
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hippocampal locations, regions that exhibit high amyloid load. In comparison,
nontransgenic control mice recruited only a few cells to the brain and the few that
were present were associated with the blood vessels. Stereological analysis
detected a significant difference in recruitment in the liver, lung and spleens
between the non transgenic and the APP+PS1 transgenic mice as. While not
significant, these trends were also confirmed using flow cytometry analysis
(Figure 2B). This significant increase in the organs of the nontransgenic mice is
most likely due to competitive recruitment of these cells to the brain tissue in the
APP+PS1 transgenic mice.
An important factor in the recruitment of monocytes is to determine which
population is recruited to the brain. In our study we isolated monocytes from
bone marrow using a magnetic cell separation kit that used CD11b as the marker
to isolate the cells. However, recent efforts have used combinations of markers in
an attempt to distinguish monocytes from macrophages, neutrophils and other
leukocytes, to identify functional subsets of monocytes (Tacke et. Al, 2006;
Djukic et al., 2006; Kato et al., 1996). CCR2-CX3CR1high monocytes that home
constitutively to tissues appear to belong to a different group than
CCR2+CX3CR1low monocytes that home only when the tissue is inflamed. The
two subsets of monocytes may exhibit different responses to pathogens, and it
will be important to determine whether they differ in expression of lectins and tolllike receptors. CCR2+CX3CR1low monocytes are hypothesized to be involved in
innate inflammatory responses, contributing to clearing debris as well as in
triggering of the adaptive response toward pathogens. In contrast cells derived
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from resident CCR2-CX3CR1high monocytes may be involved in tissue
homeostasis as populations of resident macrophages include specialized
subsets such as osteoclasts, Kupffer cells, and microglia. Thus it will be
important for us to determine exactly which population is attracted to Aβ plaques
in our transgenic mouse model. By targeting molecules restricted to
CCR2+CX3CR1low monocytes such as chemokine receptors, it may be possible
to manipulate their function in inflammatory diseases, without affecting the
potential homeostatic role of the CCR2-CX3CR1high monocytes in the brain.
Many studies have provided evidence that microglial cells are attracted to
amyloid deposits both in human samples and in rodent transgenic models that
develop this disease (Weigel et al., 2003; Weigel et al., 2004; Malm et al., 2005).
It is therefore important to study the development of these deposits, as well as
the effects they have on their cellular environment. The precise role of microglia
in AD is still under debate. The idea that an immune reaction in AD is the cause
of neurodegneration comes from many reports demonstrating that amyloid
plaques are often surrounded by microglial cells (Weigel et al., 2003; Weigel et
al., 2004; Malm et al., 2005). Some indicate that microglial activation is induced
by aggregated β amyloid (Casal et al., 2002), whereas others report that diffuse
forms may also be responsible for the immune response seen in this disease
(Takata et al., 2003; Hashioka et al., 2005).
While we have demonstrated that peripheral monocytes can be recruited
to the brains in APP+PS1 transgenic mice, the exact mechanisms that mediate
these cells to the brain parenchyma are still unclear. We and others have
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hypothesized that Aβ can cause peripherally circulating macrophages to cross
the blood brain barrier via chemokine recruitment. (Fiala et al., 1998). Alterations
in the permeability of the BBB, expression of cell adhesion molecules, and
activation of chemoattractants and their receptors are events that control the
migration of blood immune cells in the CNS. It has been proposed that these
processes are controlled by pro and anti inflammatory cytokines that are
released after a brain injury from cells normally present in the CNS, such as
astrocytes, endothelial cells and microglia (Gimbrone, 1999). It is evident that
soluble inflammatory factors are important since virtually all cytokines and
chemokines that have been studied in AD including IL-1β, IL-6, TNFα, IL-8, TGFβ and MIP-1α are upregulated (Neuroinflammation Working Group, 2000). In
addition to these soluble mediators, cell surface molecules are important in
regulating the inflammatory response in the brain. Microglial cells cultured in vitro
have been shown to display an increased migratory response upon treatment
with beta chemokines, including MCP-1, suggesting that these molecules may
play an important role in the trafficking of mononuclear phagocytes within the
brain (Peterson et al., 1997). We have shown in previous work that when MCP-1
is injected into the brains of non transgenic mice, the signal of this chemokine
can recruit peripheral monocytes to enter the brain. El. Khourey et al., crossed a
CCR2 knockout mouse with an APP transgenic mouse and showed a decreased
microglial accumulation in the Alzheimer disease brain which resulted in
increased Aβ deposition. Also, Hofman et al also demonstrated that MCP-1
expression is present in the cerebral microcirculation in tissue sections from AD
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but not control patients. However, other cell adhesion molecules may play a key
role in the recruitment of these cells. In the AD brain there is elevated expression
of ICAM-1 in the cerebral microcirculation (Frohman et al., 1991; Schoning et al.,
2002; Merrill and Benveniste, 1996). Several groups have also shown that the
transmigration of monocytes into the brain might require LFA-1 and Mac1, which
each bind ICAM-1 (Hakkert et al., 1991; Andrew D., 1998). These data, in
conjunction with our results, highlight the brain endothelium as a key regulator of
white blood cell migration across the blood brain barrier as well as an
orchestrator of events within the CNS. Similarly, the term monocytes may
describe a heterogeneous group of cells with similar appearance but different
roles in the immune system.
Many different studies have alluded to Aβ as a culprit in AD disease
progression because the 40-42 amino acid peptide is the major component of
amyloid deposits seen in postmortem AD pathology (Selkoe, 1999, Gandy. S,
2005). However, in the large number of AD cases in whom a genetic risk factor
has not yet been identified, the reasons for the excessive accumulation of Aβ in
the brain are unknown. Aβ levels are determined by the balance between Aβ
production and removal and it is possible that deficiency in the proteolytic
degradation of Aβ peptides could contribute to AD, especially late onset sporadic
AD (Iwata et al., 2000, Iwata et al, 2001, Eckman et al., 2001). The proteases
involved in the degradation and clearance of Aβ have received very little
attention, and the main mechanisms that regulate the steady state levels of Aβ in
the normal brain remain unclear.
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The parallel of NEP with Aβ in the location of the brain makes this
protease stand out among other Aβ degrading proteases as a key regulator of Aβ
degradation (Iwata et al., 2005; Saido et al., 2005; Salto et al., 2003). The active
site of neprilysin faces the extracellular side, where Aβ is hypothesized to be
released; implicating a mutual interaction between NEP and Aβ in vivo. The
synaptic and axonal localization suggests that after NEP is synthesized in the
soma it is then axonally transported to the presynaptic terminals where Aβ
degradation is likely to take place. This idea was reinforced when a recombinant
AAV vector expressing NEP was injected into the dentate gyrus of neprilysin
knockout mice. Not only was the presence of NEP detected in the injected
hippocampus, but NEP staining was present in the contralateral hippocampus
indicating that NEP was transported axonally to presynaptic sites through
afferent of neuronal circuits (Iwata et al., 2004). APP also undergoes axonal
transport to presynaptic terminals, where Aβ is generated through sequential
cleavages by β and γ secretases and released to extracellular space (Price et al.,
2000; Selkoe 2001). Therefore the sites for the degradation of Aβ and the
location of NEP seem to be closely linked to each other highlighting the important
role this protease has as a therapeutic target for the treatment of AD.
Gene therapy by gene transfer to the diseased or injured CNS provides
the basis for the development of potentially powerful new therapeutic strategies
for a broad spectrum of human neurologic disorders. Previously, several viral
systems encoding genes of interest have been injected into brains with variable
success. The retroviral vectors have shown high integration efficiency however
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they demonstrate low and unstable viral titer and the need for cell division
(Mulligan 1993; Dranoff and Mulligan 1995). Adenoviruses have also shown
efficient gene transfer and viral stability, but strong antigenicity has resulted in
unwanted side effects for patients (Kozarsky and Wilson, 1993). An additional
challenge in working with several viral vectors is that transduction often leads to
microglial activation (Bhat and Fan, 2002). Nevertheless, the literature with
respect to microglia transduction is very small. However in our study, we have
found a method to harvest, isolate and transfect monocytes and re-inject them
back into an animal within hours (Paper 2). While monocytes are available in the
circulation, the percentage of monocyte cells is much greater in bone marrow
than in the blood. It has also been shown that monocytes isolated from bone
marrow were more receptive to viral vector mediated transduction than
monocytes from mouse blood (Zeng et al, 2006). As an approach to increase
expression of NEP in a transgenic mouse model of AD, we developed an ex vivo
gene therapy method utilizing bone marrow monocytes from GFP mice. Based
on previous studies transfection efficiencies less than 10% have been
accomplished using traditional transfection techniques, including electroporation,
liposomal transfection reagents and DEAE-dextran (Mayne, Borowicz et al.
2003). We have however developed a procedure that allowed us to transfect
about 50% of monocytes within a matter of seconds (Figure 2A). These
monocytes were transfected with a NEP construct designed to express either a
secreted form of NEP or a form which lacks any enzyme activity. The NEP-M
construct was used because it allowed us to develop a control for the presence
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of an endogenous enzyme as well as explore the ability of monocytes to degrade
Aβ.
We also determined that the secreted form of NEP was extremely
effective at clearing both diffuse and compact Aβ from the brain compared to the
NEP-M plasmid which lacked any enzyme activity. There was a significant
reduction of both Aβ and Congo Red near the injection site in the NEP-S mice in
the cortex and the hippocampus compared to the NEP-M injected group (Paper
2; Figures 3 and 4). Thus removal of Aβ appears to occur through the diffusion of
the protease throughout the injection site.
The recent discovery of enhanced lesion site specific infiltration of bone
marrow derived microglial progenitors into the CNS in irradiated mice (Asheuer et
al., 2004; Hess et al., 2004; Priller et al., 2001; Tanaka et al., 2003) has raised
the possibility of using gene manipulated bone marrow cells, hematopoietic stem
cells or other types of microglial cell progenitors for site specific delivery of gene
therapy to the injured or diseased CNS (Biffi et al., 2004). Therefore we
combined the results from the time course study and the intracranial study to
develop a peripheral ex vivo gene therapy study. We decided to inject the mice
twice a week for two months based on the time course study results that
demonstrated almost all cells were gone from brain after a week. The results
from the two month study once again confirmed that injected GFP-positive
monocytes derived from the bone marrow migrate from the periphery into the
brains of APP+PS1 transgenic mice. Double labeling analyses also showed that
almost all GFP+ monocytes retained the hematopoietic marker CD11b (Paper 3;
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Figure 4). These finding are in agreement with others who have reported that
BMDCs retain a hematopoietic phenotype in the brain (Vallieres and Sawchenko,
2003; Wehner et al., 2003). In addition, we also observed cells positively labeled
for CD68, a marker for macrophages (Paper 3; Figure 5).
We have shown that the secreted form of NEP was extremely effective at
clearing both diffuse and compact Aβ from the brain compared to the NEP-M
plasmid which lacked any enzyme activity. There was a significant reduction of
both Aβ and Congo Red staining in the NEP-S mice in the cortex and the
hippocampus compared to the NEP-M and control group (Paper 3; Figures 1 and
2). The levels of Aβ were comparable to that of a 9 month old APP+PS1 mouse
indicating that the NEP-S transfected monocytes halted the progression of
amyloid deposition by up regulating NEP in the brains of these animals.
Neprilysin may play a role in degrading a variety of neuropeptides, such
as enkephalin, somatostatin, atrial natriuetic peptide, substance P, neurokinins,
cholecystokinin, nociceptin, and corticotrpoin-releasing factor, based on in vitro
experiments (Roques et al., 1993; Barnes et al., 1995; O’Cuinn et al., 1995;
Johnson et al., 1999; Sakurada et al., 2002; Turner, 2004). However, whether
these neuropeptides are in vivo substrates is unclear. For instance, the levels of
enkephalins were not increased in the brains of neprilysin knockout mice (Saria
et al., 1997), despite the fact that neprilysin is a potent enkephalin degrader,
indicating that neprilysin deficiency is compensated for by other proteases. While
increasing NEP in the brain may affect other substances, since it is involved in
the degradation of other species besides Aβ, during the two months of injections

126

we found no signs of weight loss or deteriorating health. Also when we examined
the plasma and brain regions from each mouse, we were unable to detect the
presence of the HA transgene in the plasma indicating that the effects seen were
restricted to the brain region (Paper 3; Figure 3).
While we did not actually determine if the GFP-positive cells were
phagocytosing Aβ, increasing evidence has hypothesized that microglia may play
a protective role in AD by mediating clearance of Aβ. Indeed, when we compared
the amount of amyloid in the three treatment groups, we saw a small trend in the
NEP-M treated group that may indicate peripheral derived monocytes alone
could delay the progression of AD like pathology. There is evidence from several
groups that microglia are necessary for effective removal of amyloid through
activation of various treatments. Herber et al., 2004, confirmed that LPS
treatment reduces Aβ deposition in APP/PS1 transgenic AD mice. The crossing
of APP transgenic mice with mice that overexpress TGFβ produced offspring that
had increased microglial cell activation and reduced amyloid loads (Wyss-Coray
et al., 2001). Also, blocking of complement activation reduced microglial cell
activity in APP tg mice and resulted in an increase of Aβ (Maier et al., 2008).
Imaging of mouse amyloid deposits in vivo by two photon confocal microscopy
has shown that local clearance of amyloid plaques after direct application of an
Aβ specific antibody occured in connection with the local increase of activated
microglial cells (Lombardo et al., 2003). This interaction has been hypothesized
to occur as a result of FcR mediated phagocytosis of Aβ antibody immune
complexes by microglial cells. Also, it has been reported that increased cell
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surface expression of the receptor M-CSF by microglial cells can accelearate
phagocytosis of aggregated Aβ, through increasing microglial cell expression of
FcRs for IgG (Mitrasinovic and Murphy, 2002). Each of these studies supports
the concept that in the mouse model of AD, activation of microglial cells may play
a beneficial role in reducing Aβ without causing significant neuronal damage.
The data supporting a role for microglia in Aβ clearance are convincing,
but these data also raise an important question. Why does Aβ continue to
accumulate and why does AD neuropathology develop despite continual
microglia recruitment? One possible hypothesis for the failure of microglia to stop
AD progression is that these cells become inundated by the excess amount of Aβ
produced and cannot degrade Aβ as fast as it is being generated. Another
hypothesis is that as AD progresses, the phenotype of peripheral and resident
microglia shifts towards a more pro-inflammatory state and as a result these cells
lose their Aβ clearing capabilities, resulting in increased Aβ accumulation. Also
Aβ might not continue to be seen as an antigen or the signals released from the
deposits decrease so that peripheral cells are no longer attracted to the deposits.
A final hypothesis is that monocyte infiltration across the BBB might occur less
often in older animals due to the fact that the immune response weakens with
age in AD patients (Richartz et al., 2005). In support of this possibility, Fiala et
al., 2005 found that monocytes and macrophages from AD patients displayed
ineffective

phagocytosis

of

Aβ

when

compared

with

monocytes

and

macrophages from age matched control non-AD patients. It is not clear which of
the above mechanism accouts for reduced clearance of Aβ by microglia, but
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determining a method to increase the number of effective clearing monocytes
might serve as a neuroprotective therapy to eliminate or halt the progression of
Aβ development.
There has been significant interest to identity the cell surface receptors
that mediate microglial and Aβ interaction. A number of receptors have been
shown to bind Aβ, including scavenger receptor class A (SR-A; El Khoury et al.,
1996; Paresce et al., 1996), SR-B1 (Husemann et al., 2001), the neuronal α7
nicotinic acetocholine receptor (Dineley et al., 2001; Pettit et al., 2001), the
receptor for advanced glycation end products (RAGE; Yan et al., 1996), the
formyl peptide chemotactic receptor (FPR; Lorton, 1997; Le et al., 2001), heparin
sulfate proteoglycans (Giulian et al., 1998; Scharnagl et al., 1999) and the α5β1integrin (Matter et al., 1998). However, only SR-A and RAGE have been shown
to interact with fibrillar forms of Aβ (Yan et al., 1996; El Khoury et al., 1996). It
has been hypothesized that both RAGE and SR-A can interact with Aβ, resulting
in stimulation of intracellular signal transduction pathways involved in production
of proinflammatory cytokines. Another proposed mechanism for Aβ activation of
microglia is through the receptor for advanced glycation end products (RAGE)
and macrophage colony stimulating factor (M-CSF). (Lue et al.,2001). These
receptors have been shown to bind Aβ and trigger signals leading to cellular
activation. After degradation of Aβ, M-CSF over expressed by the microglia in the
vicinity of Aβ deposits has resulted in enhanced phagocytosis of Aβ resulting in
clearance of the deposits (Mitrasinovic and Murphy, 2003).
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Aging of adaptive immunity has been greatly studied in recent years
(Grebeck-Loebenstein and Wick, 2002). However, considerably less information
is available on how aging affects the innate immune system. While there are
indications that age related changes within the innate immune system may
influence the development of age related neurodegenerative disorders such as
AD, how old age changes the reaction of microglia to stimuli such as Aβ is not
yet known. The first studies on the effect of healthy aging on microglial cells have
recently appeared. Microglial cells from non demented elderly donors showed
several abnormalities within their cytoplasmic structure, including deramification,
gnarling and fragmentation of processes (Streit et al., 2004). These changes
were interpreted to be different from physical changes that are typically seen
during microglial activation in neurodegenerative disorders.
Also the down-regulation of various proteases is implicated in the Aβ
deposition observed in human brains during the aging process. In addition to
neprilysin, several peptidases such as endothelin converting enzyme (ECE1),
ECE2, and insulin degrading enzyme (IDE) have been identified as Aβ degrading
enzymes though the use of genetic knock out and knock in mice (Eckman et al.,
2003; Farris et al., 2003; Miller et al., 2003). These proteases are likely to
contribute to overall Aβ clearance in the brain by complementing each other in a
cell or brain region specific location. NEP degrades Aβ inside secretory vesicles
and on the extracellular surface, while ECEs degrade Aβ in acidic compartments
(Eckman et al., 2001; Saido and Nakahara, 2003). Also, IDE which is primarily a
cytosolic and peroxisomal enzyme (Duckworkth et al., 1998) can be found in the
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plasma membrane (Vekrellis et al., 2000). As a result these poteases may be
collaborating to effectively remove Aβ and prevent AD. Developing a combination
therapy which encompasses each protease’s actions may then be the next step
in the development of an even more effective ex vivo gene therapy for the
removal of Aβ.
A better knowledge of the role of inflammation and protease regulation in
the development of many neurodegenerative diseases is required before we can
safely develop new therapeutics designed at preventing or reversing neuronal
damage. While an amplified immune response could be adverse to the CNS,
increasing evidence reveals that a controlled inflammatory response in the brain
might be beneficial to the maintenance and proper function of the CNS. In the
case of AD, bone marrow or blood derived monocytes would serve as an ideal
alternative to other cells employed in gene therapy because of their natural
homing abilities to the CNS under inflammatory conditions. In addition, the self
donation of bone marrow would have the advantage of being safe, widely
applicable and ethically acceptable.
Since the majority of AD cases are sporadic and do not display any clear
genetic causes, multiple factors are likely involved in the accumulation of Aβ in
AD. There is mounting data now available to link Aβ degradation in AD
pathogenesis. Aβ is a substrate of a wide range of proteases, which are likely to
contribute to the accumulation of Aβ in AD. Decreases in protease degradation
through genetic mutations and nongenetic factors, such as oxidative damage
may contribute to reduced Aβ catabolism. Current results from in vitro and animal
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models support NEP, IDE, and ECE as possible enzymes for Aβ degradation, but
data from humans remains largely missing. Measurement of brain Aβ levels and
amyloid histopathology in correlation with enzyme activity, location and
expression will help identify which of these enzymes are significant players in
AD. Information about monocytes subsets and their functions will also impact our
understanding of diseases and the design of therapeutic strategies. Whether
monocytes are predetermined to home to specific tissues, and if so, when and
where they gain the chemotactic receptors and adhesion molecules that facilitate
their entry into these tissues will represent critical questions for future research.
We have presented new evidence that the peripheral monocyte population may
be more complex than previously thought. There seems to be a scenario
beginning to develop, where resident CNS microglia can interact with functionally
different populations of peripheral monocytes. Harnessing the peripheral immune
system to pharmacologically control brain Aβ levels may serve as a powerful new
tool to improve recovery and repair brain damage for the treatment of AD.
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